Background
More information about the pattern of behavioural and psychological symptoms of dementia (BPSD) in the course of dementia is needed to inform patients and clinicians and to design future interventions.

Aims
To determine the persistence and incidence of BPSD and their relation to cognitive function, in individuals with dementia or in cohorts investigated for dementia onset.

Method
A systematic literature review analysed the baseline prevalence, persistence and incidence of 11 symptoms. The review was conducted according to established guidelines with the exception that we could not exclude the possibilities of bias in the studies examined.

Results
The 59 included studies showed considerable heterogeneity in their objectives and methods. The symptoms hyperactivity and apathy showed high persistence and incidence; depression and anxiety low or moderate persistence and moderate incidence; and psychotic symptoms low persistence with moderate or low incidence.

Conclusions
Despite heterogeneity across studies in terms of setting, focus and length of follow-up, there were clinically relevant differences in the longitudinal courses of different BPSD. Apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.

Declaration of interest
None.

Copyright and usage
© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.

Behavioural and psychological symptoms of dementia (BPSD) include affective symptoms, psychotic symptoms, non-aggressive agitation, irritability, wandering, elation and sleep problems. They have a high prevalence in dementia and nearly all people with dementia have at least one of these symptoms during the course of the disease. Such symptoms have negative effects on the quality of life of both patients and caregivers and are associated with increased costs of care. Better treatment and management of the symptoms are important, particularly as there is no effective treatment to alter the course of the underlying cognitive and functional decline. In order to design and conduct clinical trials for the treatment of BPSD, more information about the pattern of these symptoms in the different stages of dementia is needed to identify the best stage to intervene. In addition, insights into the extent to which BPSD occur over the course of dementia will help patients and care providers to plan for the future. Cross-sectional studies have shown that BPSD can occur at any time during the development of dementia. Their prevalence may increase from mild to severe dementia, whereas other studies suggest a non-linear course with the highest prevalence seen in the intermediate stages of disease. Symptoms may persist or be episodic over time, and this may differ between symptoms. Evidence from longitudinal studies is limited and has not been brought together systematically. Two reviews on the course of BPSD specifically in care-home residents have been published recently. They included a small number of studies (28 and 18) and concluded that the course of BPSD varied considerably between studies and between individual symptoms.

Our aim was to determine the longitudinal course of BPSD in individuals with dementia or in cohorts studied for dementia onset. We also investigated the persistence and incidence of symptoms and how persistence of BPSD over time relates to cognitive function. This review builds on five previous reviews by some of the same authors.

Method
Electronic searches of PubMed, EMBASE, Cinahl and PsycINFO databases were undertaken to identify potentially relevant articles published before March 2013. Search terms included text and MeSH terms for BPSD, dementia and longitudinal study (see online Fig. DS1). Two authors (R.v.d.L. and B.S.) independently searched titles and abstracts for potentially relevant articles. Following this, full text selection was completed by two authors: R.v.d.L. and A.M.P. (or B.S.). References of included studies were
Data were extracted independently and in duplicate (R.v.d.L. and B.S. or E.E.). Details extracted from each paper included setting, participant recruitment method, number of participants, follow-up time, BPSD and their measurement, number of BPSD measurements, population age (mean and range), baseline Mini-Mental State Examination (MMSE) score, \(^{14}\) baseline BPSD prevalence, statistical methods used, covariates taken into account and findings on the persistence, incidence and association of BPSD with cognitive function. Risk of bias was not formally assessed in a quality assessment. Findings were divided by dementia severity and BPSD. Dementia severity was defined using MMSE categories based on clinical practice guidelines from the National Institute for Health and Care Excellence (NICE): mild dementia (MMSE score 21–26), moderate dementia (MMSE 15–20), moderately severe dementia (MMSE 10–14) and severe dementia (MMSE <10).\(^ {15}\) When no MMSE score was reported, equivalent cut-off scores from the Cambridge Cognitive Examination (CAMCOG), modified MMSE, Clinical Dementia Rating (CDR) scale and the Alzheimer’s Disease Assessment Scale (ADAS) were used.\(^ {16–22}\) By use of results from factor analyses and cluster analysis reported in the literature, \(^ {10}\) symptoms were grouped into affective symptoms (comprising depression, anxiety and apathy), psychosis (comprising delusions and hallucinations), hyperactivity (comprising irritability, agitation and wandering), elation and sleep problems.

Where possible the persistence of symptoms was reported as the percentage of people with a certain symptom at baseline who also had the symptom at the next measurement or for whom the symptom persisted during the entire follow-up period. Incidence was reported as the percentage of people without symptoms at baseline who had developed new symptoms at the next measurement or during the entire follow-up period. Results from a multistate model were reported when available. Studies investigating the association between BPSD and cognitive function were summarised by reporting the analysis methods (e.g. Cox proportional hazards model, latent class linear mixed model or logistic regression model), covariates taken into account, BPSD and their measurement, number of BPSD symptoms and ‘moderate’ if the results were intermediate or found that results were lower than for most of the other symptoms in the studies that included several BPSD. Prevalence, persistence and incidence were summarised as ‘low’ if the majority of studies found that the results were lower than that of most of the other symptoms included, ‘high’ if the majority found that results were higher than for most of the other symptoms and ‘moderate’ if the results were intermediate or mixed. The range of the results was reported for each symptom.

Symptoms

Included symptoms are shown in Table 1 and their baseline prevalence is summarised in Fig. 1. Full details of each symptom, its definition, the instrument used for its measurement and the baseline prevalence can be found in online Table DS2. Affective symptoms were the most frequently studied (37 studies), with 24 studies reporting on depression only. Anxiety was studied in 11 studies, apathy in 4, and 2 studies reported on a factor of affective symptoms. Psychotic symptoms were studied in 26 studies (delusions in 20, hallucinations in 21, misidentifications in 1, psychosis symptoms combined in 5). Hyperactivity symptoms were the most frequently studied (37 studies), with 24 studies reporting on irritability only; non-aggressive agitation (often including pacing or wandering) (16 studies), wandering (4 studies) or a factor of hyperactivity symptoms (6 studies), were studied in 30 studies. Elation was measured in only 5 studies and sleep problems in 9. Many different instruments exist to measure and define BPSD,\(^ {12}\) and 28 different instruments were used across the included studies. The Neuropsychiatric Inventory (NPI) was used in 8 studies.\(^ {23}\) Five studies used the total score of a BPSD instrument, rather than presenting individual symptom profiles.

Prevalence

The baseline prevalence varied widely across the studies (see Fig. 1). Generally, higher baseline prevalence was reported by studies that included a population with moderate or moderately severe dementia than by studies that included those with severe dementia only. A higher prevalence of symptoms was also seen in studies that recruited participants from psychiatric settings rather than from the population or institutional care settings (e.g. for depression: psychiatric settings 20–57%, institutional care 8–20%, population over 22%). Studies with a younger mean age typically showed a higher symptom prevalence (e.g. for delusion: ≤75 years 24–40%, 75+ years 9–22%). There may also be differences by BPSD instrument. For example, studies that measured symptoms using the BEHAVE-AD typically showed a higher prevalence than studies using the NPI.
Course of symptoms of dementia

Symptom persistence and remission

The persistence and stability of symptoms or the change in symptom scores over time were considered for each of the five symptom domains separately. Figure 2 summarises the results of studies investigating the persistence of depression, hallucination and irritability (see online Fig. DS2 for the persistence of all symptoms). Detailed findings are available in online Table DS3.

Depression, anxiety and apathy

A large variation in persistence of affective symptoms was seen, with great intra-individual variability. Aalten et al reported a relatively low persistence of depression, anxiety and apathy, whereas Haupt et al reported a persistence of depression of up to 59% over a 2-year period. Anxiety and apathy may be more persistent over time than depressive symptoms, although two studies reported that anxiety was less persistent than depression. Wetzels et al (study not included in the figures because it described only the persistence over each observation) found that resolution of anxiety was consistently higher than persistence of symptoms, whereas apathy showed a variable course. Where change was modelled statistically, affective symptoms were generally found to be stable without significant change over time.

Delusions, hallucinations and misidentifications

The persistence of psychotic symptoms was mostly below 30% (5 studies), although one study reported that the 6-month persistence of delusions was 59% and hallucinations 52%. Further, multistate models by Eustace et al showed delusions were persistent over 12 months in 65%. Generally, hallucinations were less persistent than symptoms of delusion, although two studies found similar results for delusions and hallucinations, and two studies found hallucinations were more persistent than delusions.
Irritability, agitation and wandering

Hyperactivity symptoms were mostly persistent, with one study showing that up to 76% of individuals had persistent symptoms of agitation over 2 years.\textsuperscript{27} Studies that investigated several hyperactivity symptoms found that agitation was more persistent than irritability.\textsuperscript{18,26,27} A study investigating several symptoms of irritability found that verbal aggression was the most common and longest-lasting form of aggressive behaviour, whereas aggressive resistance and physical aggression were most likely to persist until death.\textsuperscript{36} King-Kallimanis et al found that wandering status was more likely to change from wandering to non-wandering rather than the reverse and that wandering was a temporary phase for approximately half of care-home residents who were admitted as wanderers.\textsuperscript{37} Several authors analysed the course of hyperactivity over time using repeated measures analysis or a latent class linear mixed model. Garre-Olmo et al reported that over a 2-year period hyperactivity symptoms were mostly low and smoothly increasing (this pattern was found in two-thirds of participants).\textsuperscript{32} Cohen-Mansfield et al found that aggressive behaviours increased over time whereas physically non-aggressive behaviours did not change significantly.\textsuperscript{38}

Elation

The persistence of elation was investigated in only two studies. Wetzel\textsuperscript{e} et al found in severe dementia that, for each two consecutive assessments at 0–6 months, 6–12 months, 12–18 months and 18–24 months, symptoms were stable in 39%, 18%, 3% and 3% respectively.\textsuperscript{31} Over a total follow-up period of 2 years Aalten et al found in moderate dementia that symptoms were stable over a 6-month period in 2%, whereas for none of the participants did symptoms persist over 12 months, 18 months or 24 months.\textsuperscript{26} Therefore, these results suggest that elation is not persistent.

Sleep problems

Most studies that investigated sleep problems (4 studies) reported low persistence,\textsuperscript{26,29,30} or a fluctuating course.\textsuperscript{31} In only one study were sleep symptoms reported to be persistent.\textsuperscript{28}

---

**Fig. 1** Baseline prevalence of behavioural and psychological symptoms; see online Table DS2 for more details. Numbers are the reference numbers of the included studies. ‘Excluded’ indicates that the study excluded participants with a particular symptom at baseline (i.e. the prevalence was 0%). Twenty-six studies that did not report baseline prevalence or reported on a population already included in the figure are omitted. Dep, depression; Anx, anxiety; Apa, apathy; Del, delusions; Hal, hallucinations; Psy, psychosis; Irr, irritability; Agi, agitation; Wan, wandering; Ela, elation; Sle, sleep problems. *Subsymptom reported separately.
Fig. 2  Persistence of (a) depression, (b) irritability and (c) hallucinations. Squares indicate the reported percentage where the symptom persisted over the measurement period and the lines indicate 95% confidence intervals. The name of the first author is given next to the corresponding findings. If the study reported the persistence over several intervals, it is included in the figure more than once. Next to the name of the author the total follow-up time (in months unless specified) and the number of visits are reported. For example, Aalten et al measured symptoms at 5 visits over 24 months and reported on the percentage of participants with depression present at any consecutive period of 6 months (depression present at 2 visits), 12 months (present at 3 visits), 18 months (present at 4 visits) or 24 months (present at 5 visits).
**Incidence and absence of symptoms**

Online Table DS4 and Fig. DS3 show the incidence of symptoms and the percentage of participants who did not have symptoms during the follow-up period. A summary is shown in Fig. 3.

**Depression, anxiety and apathy**

Affective symptoms commonly develop in people with dementia. Over a 1-year period a high or moderate depression incidence of up to 37% was reported by eight studies, whereas in others the onset of depression was low compared with other symptoms. The incidence of apathy has been reported to be particularly high: 64% over 2 years, and 14–27% over a 6-month period.

**Delusions, hallucinations and misidentifications**

In four studies the probability of new-onset hallucinations was reported to be low, whereas in another four incidence was reported to be moderate or high. Other psychotic symptoms including delusions showed a consistently moderate incidence (11 studies). The probability of the onset of sleep problems was reported in four studies. No consistent findings were reported: at each 6-month period the incidence in one study was 15%, and in another four incidence developed in 31%, whereas over a total follow-up of 2 years symptoms developed in 31% and over 4 years in 11%.

**Irritability, agitation and wandering**

All included studies that compared the incidence of hyperactivity with other symptoms (9 studies) concluded that the incidence of hyperactivity was high or moderate. Although the incidence of agitation might be particularly high, wandering might develop less often.

**Elation**

The incidence of elation was investigated by three studies that used the NPI. Aalten et al reported a cumulative incidence over a 2-year period in 5%, whereas Wetzel et al reported that for each 6 months of observation new symptoms were seen in 3–4% and Gillette-Guyonnet et al reported that new symptoms developed during a maximum follow-up of 4 years in 8%. These results suggest that the incidence of elation is low.

**Sleep problems**

The probability of the onset of sleep problems was reported in four studies. No consistent findings were reported: at each 6-month period the incidence in one study was 15%, and in another 2–8%, whereas over a total follow-up of 2 years symptoms developed in 31% and over 4 years in 11%.

**Association with cognitive function**

The results of studies investigating the association between the course of BPSD and cognitive function (25 studies) are summarised in online Table DS5.

**BPSD and subsequent cognitive function**

Eight studies investigated the association between depression and subsequent cognitive decline or development of dementia in those without dementia at baseline. Those with persistent depression showed significant decline over time in global cognitive function, memory, processing speed, recall and attention. Some found a slight increase in depression score before dementia diagnosis compared with those who did not develop dementia, whereas others did not find a significant change in depression before dementia diagnosis. In those with dementia, associations with progression of cognitive function were found for psychosis, hyperactivity, and depression. Two studies investigated the link between BPSD and mild cognitive impairment. In one study persistence of depression was associated with progression to dementia, whereas another reported no difference in persistence between those who were cognitively stable and those who progressed to dementia.

**Cognitive function and BPSD development**

In individuals with dementia, psychosis, hyperactivity, agitation and physical aggression were associated with greater cognitive impairment. In contrast, Marin et al found no association in dementia between cognitive impairment and depression, delusion, agitation and irritability. Four studies found that symptoms increased with cognitive decline in the early stages of dementia and were most commonly seen in moderate dementia, followed by a declining or stable course in the final stages of dementia. Over a 1-year period a high or moderate depression incidence of 2–8% was reported, whereas over a total follow-up of 2 years symptoms developed in 3–4%, and in another four incidence developed in 11%.

**Comparison of symptoms**

We summarised the studies investigating several BPSD to compare baseline prevalence, stability, incidence and association with cognitive function for each of the symptoms (Table 2). Some symptoms were studied more often than others, and evidence is lacking for infrequently studied symptoms such as wandering (included in only one study investigating several BPSD), and apathy and elation (included in only four studies). Depressive symptoms were most often studied (included in 12 of the 13 studies investigating several BPSD). Compared with other symptoms, the results suggest that the persistence and incidence of depressive symptoms are moderate. Anxiety seems to be less prevalent and was reported to have a moderate persistence and incidence. The few studies investigating apathy suggest a high prevalence, persistence and incidence of symptoms. The prevalence, persistence and incidence of psychotic symptoms were suggested to be low to moderate, and may be particularly low for hallucinations. Symptoms of hyperactivity were most frequently seen and the majority of studies reported a higher persistence and incidence compared with other symptoms.

**Discussion**

This systematic review confirms that BPSD are common and relatively persistent in individuals with dementia. The results suggest there are differences between symptoms: hyperactivity and apathy showed high persistence and incidence; depression and anxiety low or moderate persistence and moderate incidence; and psychotic symptoms low persistence and a moderate or low incidence. Studies of the association between BPSD and cognitive function suggest that in those without dementia the presence of depression is associated with subsequent cognitive decline. In
Fig. 3  Incidence of (a) depression, (b) irritability and (c) hallucinations. See Fig. 2 for an explanation of the symbols. NR, not reported.
those with dementia, psychosis, hyperactivity, agitation and physical aggression were associated with greater cognitive impairment.

**Strengths and limitations**

Standardised procedures were used for the literature search and data extraction, including double reading to ensure quality. However, no established search term for BPSD exists and therefore relevant studies may have been missed. The reference lists of included articles and reviews were searched to minimise the number of missed articles. The review included studies with a high degree of heterogeneity in study design and population characteristics, including large differences in the period over which the persistence and incidence was reported (1 month to 4 years), the total follow-up time (3 months to 14 years), the number of symptoms measured, dementia severity, recruitment setting and mean age. This made cross-study comparisons difficult and a meta-analysis was not possible. We were not able to investigate whether the course of BPSD differs between types of dementia as only five of the 59 studies reported findings by dementia type. We adhered to most of the items of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see online Table DS6). Although we have reported on a range of factors that might influence the quality of the study, risk of bias was not formally assessed in a quality assessment. Our review therefore does not meet items 12, 15, 19 and 22 of the guidelines. Bias in the included studies may have led to an overestimate or underestimation of the prevalence of symptoms, measured dementia severity, recruitment setting and mean age. This made cross-study comparisons difficult and a meta-analysis was not possible. We were not able to investigate whether the course of BPSD differs between types of dementia as only five of the 59 studies reported findings by dementia type.

**Table 2 Results of 13 studies reporting at least two behavioural and psychotic symptoms of dementia**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Number of studies</th>
<th>Baseline prevalence (%)</th>
<th>Persistence (%)a</th>
<th>Incidence (%)b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affective</td>
<td>12</td>
<td>High</td>
<td>Moderate</td>
<td>Moderate</td>
</tr>
<tr>
<td>Depression</td>
<td>12</td>
<td>High (8–57%)</td>
<td>Moderate (16–70)</td>
<td>Moderate (10–73)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>8</td>
<td>High (17–52%)</td>
<td>Moderate (17–52)</td>
<td>Moderate (12–38)</td>
</tr>
<tr>
<td>Apathy</td>
<td>4</td>
<td>High (19–51)</td>
<td>High (20–55)</td>
<td>High (27–64)</td>
</tr>
<tr>
<td>Psychosis</td>
<td>13</td>
<td>Low</td>
<td>Moderate</td>
<td>Moderate</td>
</tr>
<tr>
<td>Delusions</td>
<td>10</td>
<td>Moderate (9–40)</td>
<td>Low (0–82)</td>
<td>Moderate (5–84)</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>11</td>
<td>Low (0–18)</td>
<td>Low (0–52)</td>
<td>Low (4–43)</td>
</tr>
<tr>
<td>Hyperactivity</td>
<td>12</td>
<td>High</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Irritability</td>
<td>9</td>
<td>High (6–57)</td>
<td>Moderate (12–80)</td>
<td>Moderate (10–69)</td>
</tr>
<tr>
<td>Agitation</td>
<td>7</td>
<td>High (18–87)</td>
<td>Moderate (21–77)</td>
<td>High (19–80)</td>
</tr>
<tr>
<td>Wandering</td>
<td>1</td>
<td>NR</td>
<td>High (60)</td>
<td>NR</td>
</tr>
<tr>
<td>Elation</td>
<td>4</td>
<td>Low (3–9)</td>
<td>Low (2–39)</td>
<td>Low (4–5)</td>
</tr>
<tr>
<td>Sleep problems</td>
<td>7</td>
<td>Moderate (6–11)</td>
<td>Low (10–57)</td>
<td>Low (8–31)</td>
</tr>
</tbody>
</table>

NR, not reported.

a. Percentage of symptoms persistent over 3 months or more.
b. Percentage incidence over 3 months or more.

and symptoms were mostly shown to be persistent, stable or increasing. The incidence reported by the studies using the NPI was low or moderate compared with studies using other instruments. Loss to follow-up is a challenge in longitudinal studies, and we have reported the number of participants at the end of the follow-up period for the included studies (online Table DS1). There was large variation in follow-up completion (24–100%, although often not reported) and reasons for leaving the study were often not reported. Persistence of BPSD may be associated with mortality and with refusal to participate in follow-up interviews, and differences in follow-up completion may have influenced the results. Furthermore, we have used study baseline as a proxy for disease and symptom onset and this may have affected the findings on the persistence of symptoms. Symptom course may be influenced by pharmacological or non-pharmacological interventions. Although there was large variation in medication use between study populations, in the majority of studies that included a sensitivity analysis the results were not altered when taking into account medication use. As we are not aware of a formal definition of high prevalence, persistence or incidence, we summarised the findings as ‘low’ if the majority of studies found that the results were lower than that of most of the other symptoms included, ‘high’ if the majority found that results were higher than for most of the other symptoms and ‘moderate’ if the results were intermediate or mixed.

**Interpretation of findings**

**Prevalence**

The prevalence of symptoms varied across the studies and between symptoms. Depression, apathy, irritability, agitation and wandering showed a high prevalence, whereas the prevalence of anxiety, hallucination and elation was low. Some studies consistently reported a relatively low prevalence of symptoms, whereas others consistently reported a relatively high prevalence. Differences might be due to variability in study design, population characteristics or measurement of symptoms. Indeed, a higher prevalence of symptoms was generally seen in studies that recruited participants with less severe dementia, in studies that recruited from psychiatric settings rather than from the population or institutional care settings, and in studies with a younger mean age. There may also be differences due to the BPSD instrument used.
Persistence

Large differences in persistence were seen across symptom groups and individual symptoms. Affective symptoms (including depression, anxiety and apathy) generally showed a moderate persistence, although a limited number of studies reported persistence of apathy to be high and in one study it was reported to be higher than for any other symptom. Persistence of psychosis was low to moderate. In contrast, hyperactivity symptoms showed a high persistence. This is an issue of concern as these symptoms are among those most problematic for caregivers. A low persistence was seen for elation and sleep problems. Differences in symptom persistence may reflect the nature of the symptom or might be explained by factors such as more widely available treatment options for depression and anxiety. Differences in dementia severity and baseline BPSD prevalence are likely to have affected results on persistence of symptoms. Persistence may be higher in those with more severe cognitive impairment at baseline, and a higher BPSD prevalence. However, associations between study characteristics and results could not be tested because of the large degree of heterogeneity in study design and population characteristics.

Incidence

The results suggest that affective symptoms and hyperactivity symptoms commonly develop in people with dementia. Large differences in reported incidence were seen between studies. For example, the reported incidence of depression ranged from 12% over a mean follow-up period of 32 months, to 73% over a maximum follow-up period of 9.3 years. Differences in study design and differences in baseline prevalence of symptoms are likely to have influenced the results. For example, the reported incidence might be higher in studies that reported a high baseline prevalence, compared with studies with a low baseline prevalence, although no formal analysis of the association between study characteristics and incidence was possible.

Role of cognition

The presence of depression before the onset of dementia was associated with subsequent cognitive decline. In dementia, psychosis, hyperactivity, agitation and physical aggression were associated with greater cognitive impairment. Symptoms may be most common in moderate dementia, followed by a declining or stable course in the final stages of dementia. However, heterogeneity in the pattern of findings across studies investigating the associations between BPSD and cognitive function prevented us from drawing more specific conclusions. The heterogeneity of results does, however, suggest that BPSD do not solely arise secondary to cognitive impairment.

Study implications

The results from this systematic review suggest that some symptoms such as hyperactivity are more persistent than others such as elation and sleep problems. In particular apathy, irritability, agitation and wandering showed a high persistence. These symptoms should be targeted in clinical trials to improve management and intervention. Clinical trials typically follow participants with more severe dementia over a short period. However, results presented here show that symptoms may persist over long periods until death, and may be most common in moderate dementia. Clinical trials focusing on the earlier stages of dementia with a long follow-up time might therefore be particularly informative. Results could also inform patients and care providers about which symptoms are most likely to recur, so that measures can be put in place to reduce their impact. Recommendations for monitoring of patients and symptom management interventions are outlined in guidance by the Alzheimer’s Society.

Future research

The heterogeneity in methods and results emphasises the importance of clearly reporting the study design, population characteristics and symptom definitions. Table 1 shows that studies typically included younger populations with moderate dementia, whereas studies recruiting those with mild or moderate dementia from the population or from primary care settings were lacking. As BPSD patterns may differ in these populations, they should be the focus of future studies. In addition, all included studies were conducted in high-income countries and the findings may therefore not be applicable outside these settings. Apathy was infrequently studied, and as the limited results suggest that it may have a high persistence and incidence, we recommend that this symptom should be the focus of future studies on symptom course.

These methodological issues reiterate the findings from several of our previous reviews. A review of reviews showed a focus on individual symptoms (particularly depression), raised the question how best to define and measure BPSD within and across populations, and recommended reporting more clearly the characteristics of the population, the inclusion and exclusion criteria and how BPSD were defined and measured. Two reviews concluded that there were many instruments to measure BPSD, of which the NPI – a short, informant-based questionnaire measuring ten symptoms – has been cited most frequently and should form the core of any battery, although researchers choosing instruments should carefully address any gaps in its content with regard to their research question. In a guest editorial we discussed that the populations used in studies of depression and BPSD are often not quite comparable and that the results therefore cannot be readily extrapolated. Finally, we showed that studies investigating symptom groups show relatively consistent results, although there remains a large amount of individual variability.

Study covariates that may be associated with higher persistence of BPSD, including impairment in activities of daily living, as well as medication use, could improve understanding of potential mechanisms involved in the presence and persistence of BPSD. Environmental factors such as overstimulation and a person’s surroundings, as well as physical factors such as pain and dehydration, are recognised as important triggers for BPSD. These factors are often difficult to capture and have not been investigated in the studies included here.

Clinical implications

Our findings underscore the existing evidence that BPSD are common in dementia and that they are also relatively persistent. Different symptoms have a variable course over time: for example, psychotic symptoms have relatively low persistence – that is, they may resolve during the course of the dementia. In contrast, apathy emerged as the only individual symptom with high baseline prevalence, high persistence and also a high incidence during the course of the dementia. Thus, increased interest in apathy as a possible early sign of dementia, as a marker for underlying brain changes and as a sign of progression of dementia seems entirely warranted. Although hyperactivity as a whole also had high baseline prevalence, high persistence and high incidence over time, the various symptoms subsumed under hyperactivity mean that it
is not a unitary phenomenon. These findings are relevant to clinicians as they indicate which symptoms may be expected to persist or to occur anew, and therefore give a better understanding of the natural history of BPSD which, in turn, can influence approaches to management and treatment.

Rianne M. van der Linde, PhD, Institute of Public Health, University of Cambridge, Tom Denning, PhD Psych, Institute of Mental Health, University of Nottingham, Blossom C. M. Stephen, PhD, Institute of Health and Society, Newcastle University, A. Matthew Prina, PhD, Institute of Psychiatry, King's College London, Elizabeth Evans, PhD, Institute of Health and Society, Newcastle University, Carol Brayne, MD, Institute of Public Health, University of Cambridge, UK.

Correspondence: R. van der Linde, Department of Public Health and Primary Care, Herchel Smith Building, Forvie Site, Robinson Way, Cambridge CB2 0SR, UK. Email: rv23@medschl.cam.ac.uk

First received 18 Mar 2014, final revision 19 Dec 2015, accepted 27 Feb 2016

Funding

R.v.d.L. received a studentship from the National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Cambridgeshire & Peterborough. A.M.P. was supported by the Medical Research Council (MRC RG56433 and MR/K021907/1).

References


Fig. DS1 Overview of the search terms
Table DS1 Characteristics of included studies
Table DS2 Definition and baseline prevalence of BPSD
Fig. DS2 Persistence of BPSD reported in included studies
Table DS3 Persistence and remission of symptoms in those with symptoms at baseline
Table DS4 Incidence and absence of symptoms in those without symptoms at baseline
Fig. DS3 Incidence of BPSD reported in included studies
Table DS5 Association BPSD and cognitive function
Table DS6 Adherence to the PRISMA reporting guidelines
Online reference list of included studies
### Fig DS1  Overview of the search terms

<table>
<thead>
<tr>
<th>DEPRES</th>
<th>ANXIETY</th>
<th>APATHY</th>
<th>SLEEP</th>
<th>IRRITABI</th>
<th>PSYCHO</th>
<th>WANDER</th>
<th>ELATION</th>
<th>AGITATI</th>
<th>BPSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>MeSh</td>
<td>Text[tiab]</td>
</tr>
<tr>
<td>Depressive disorder</td>
<td>Anxiety disorders</td>
<td>Apathy</td>
<td>Sleep disorders</td>
<td>Irritable mood</td>
<td>Psychotic disorders</td>
<td>Wandering behavior</td>
<td>Euphoria</td>
<td>Psychomotor agitation</td>
<td>“neuropsychiatric symptoms”</td>
</tr>
<tr>
<td>Depres</td>
<td>Anxiety</td>
<td>Apathy</td>
<td>Sleep</td>
<td>Irritability</td>
<td>Psychotic</td>
<td>Wandering</td>
<td>Elation</td>
<td>Agitation</td>
<td>“neuropsychiatric symptoms”</td>
</tr>
<tr>
<td>Dysphoria</td>
<td>Anxious</td>
<td>“lack of interest”</td>
<td>Sleep</td>
<td>Irritability</td>
<td>Psychotic</td>
<td>Stalking</td>
<td>Euphoria</td>
<td>Agitation</td>
<td>“neuropsychiatric symptoms”</td>
</tr>
<tr>
<td>Depression</td>
<td>Depressed</td>
<td></td>
<td></td>
<td></td>
<td>Disorders</td>
<td></td>
<td>Disinhibition</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**AND Dementia:** Dementia [Mesh] OR dementia* [tiab] OR alzheimer* [tiab] OR “lewy body” [tiab] OR “lewy bodies”[tiab] OR frontotemporal [tiab]

**AND Longitudinal study:** Longitudinal studies [Mesh] OR longitudinal[tiab] OR prospective[tiab] OR “follow-up study”[tiab]

Depres: Depressive symptoms; Sleep: sleep problems; Irritabi: Irritability; Psycho: Psychosis; Wander: Wandering; Agitati: Agitation; BPSD=Behavioural and Psychological Symptoms of Dementia

Note: Shown are the search terms used in Pubmed, the MeSh terms used in the other literature databases may differ slightly.
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Details setting</th>
<th>Reports</th>
<th>Months follow-up</th>
<th>n BPDS measures</th>
<th>Time between measures (months)</th>
<th>n at baseline</th>
<th>n with complete follow-up</th>
<th>Baseline MMSE</th>
<th>Dementia type</th>
<th>Age minimum</th>
<th>Age mean</th>
<th>BPDS instrument</th>
<th>Interview</th>
<th>BPDS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 Eustace</td>
<td>2002</td>
<td>DC</td>
<td>National referral centre for people with memory disorders, Ireland</td>
<td>Per, Inc</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>216</td>
<td>52</td>
<td>21.6</td>
<td>AD</td>
<td>NR (SD 7.8)</td>
<td>73.3</td>
<td>BEHAVE-AD</td>
<td>INF</td>
<td>Dep, Anx, Irr,</td>
</tr>
<tr>
<td>16 Clare</td>
<td>2012</td>
<td>DC</td>
<td>Memory clinics in North Wales, UK</td>
<td>Per</td>
<td>20</td>
<td>3</td>
<td>8-12</td>
<td>101</td>
<td>51</td>
<td>24.2 (18+)</td>
<td>AD, VD, mixed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dep, Anx, Total score</td>
</tr>
<tr>
<td>52 Tschanz</td>
<td>2011</td>
<td>PB</td>
<td>Cache County Study, USA</td>
<td>Per</td>
<td>Mean 3.8 yrs., max 12.9 yrs.</td>
<td>Mean 1.9</td>
<td>NR</td>
<td>328</td>
<td>33%</td>
<td>21.9</td>
<td>AD</td>
<td></td>
<td></td>
<td>85.9</td>
<td>NPI</td>
<td>INF</td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39 Levy</td>
<td>1996</td>
<td>NR</td>
<td>NR (clinical trial), USA</td>
<td>Per, Inc</td>
<td>12</td>
<td>5</td>
<td>3</td>
<td>215</td>
<td>181</td>
<td>20</td>
<td>AD</td>
<td>51</td>
<td>70.8</td>
<td>ADAS</td>
<td>INF</td>
<td>Dep, Agi/Wan, Psy</td>
</tr>
<tr>
<td>8 Berger</td>
<td>2005</td>
<td>DC</td>
<td>Outpatient Memory Clinic of university, Germany</td>
<td>Per, Inc</td>
<td>24</td>
<td>5</td>
<td>3-6</td>
<td>45</td>
<td>18</td>
<td>20</td>
<td>NR</td>
<td>48</td>
<td>70.6</td>
<td>BEHAVE-AD</td>
<td>CLIN?</td>
<td>Dep, Anx, Hal, Del, Irr, Agi/Wan, Sile</td>
</tr>
<tr>
<td>29 Holtzer*</td>
<td>2005</td>
<td>DC</td>
<td>3 sites in USA and 2 sites in Europe (Paris and Greece) (1b)</td>
<td>Cog</td>
<td>max: 14 yrs.</td>
<td>max: 28</td>
<td>6</td>
<td>536</td>
<td>130 (5 yrs.)</td>
<td>NR</td>
<td>AD</td>
<td>74</td>
<td></td>
<td>CUSPAD</td>
<td>INF</td>
<td>Dep</td>
</tr>
<tr>
<td>51 Scarmeas**</td>
<td>2007</td>
<td>DC</td>
<td>See 1b</td>
<td>Per, Cog</td>
<td>max:14 yrs.</td>
<td>max:25</td>
<td>6</td>
<td>497</td>
<td>NR</td>
<td>16+</td>
<td>AD</td>
<td>49</td>
<td>74</td>
<td>CUSPAD</td>
<td>NR</td>
<td>Agi, Irr, Wan</td>
</tr>
<tr>
<td>50 Scarmeas**</td>
<td>2002</td>
<td>DC</td>
<td>See 1b</td>
<td>Inc</td>
<td>max: 9.3 yrs, 5.5 yrs.</td>
<td>NR</td>
<td>6</td>
<td>87</td>
<td>NR</td>
<td>AD</td>
<td></td>
<td>70.7</td>
<td></td>
<td>CUSPAD</td>
<td>INF</td>
<td>Dep, Behavioural (Agi, Wan, Irr, Hal, Del, Mis)</td>
</tr>
<tr>
<td>20 Devanand**</td>
<td>1997</td>
<td>DC</td>
<td>3 medical centres, USA (1a)</td>
<td>Per, Inc</td>
<td>5 yrs. (mean 3 yrs.)</td>
<td>7</td>
<td>6</td>
<td>235</td>
<td>137</td>
<td>NR</td>
<td>AD</td>
<td>82.1% 65+</td>
<td>73.1</td>
<td>CUSPAD</td>
<td>INF</td>
<td>Dep, Irr, Agi/Wan, Hal, Del, Mis</td>
</tr>
<tr>
<td>28 Holtzer**</td>
<td>2003</td>
<td>DC</td>
<td>See 1a</td>
<td>Per, Inc, Cog</td>
<td>3 yrs.</td>
<td>11</td>
<td>6</td>
<td>236</td>
<td>102</td>
<td>NR</td>
<td>AD</td>
<td>72.7</td>
<td></td>
<td>CUSPAD</td>
<td>INF</td>
<td>Irr, Agi/Wan, Hal, Del, Sile, Eat, Dis</td>
</tr>
<tr>
<td>24 Garre-Olmo</td>
<td>2010</td>
<td>DC</td>
<td>Memory Clinic of hospital, Spain</td>
<td>Per</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>491</td>
<td>253</td>
<td>NR</td>
<td>AD</td>
<td>48</td>
<td>75.2</td>
<td>NPI</td>
<td>INF</td>
<td>Apa, Dep, Anx, Irr, Agi/Wan, Hal, Del, Sile, Eat, Dis</td>
</tr>
<tr>
<td>1 Aalten*</td>
<td>2005</td>
<td>DC</td>
<td>Outpatients of Memory Clinic of University Hospital, or psychiatry clinic, The Netherlands (2)</td>
<td>Per, Inc</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>199</td>
<td>99</td>
<td>18.1</td>
<td>AD, VD, LBD, mixed</td>
<td>53</td>
<td>76.4</td>
<td>NPI</td>
<td>INF</td>
<td>Apa, Dep, Anx, Irr, Agi/Wan, Hal, Del, Sile, Eat, Dis</td>
</tr>
<tr>
<td></td>
<td>Aalten</td>
<td>Gillette-Guyonnet</td>
<td>Zahodne</td>
<td>Rosen</td>
<td>Paulsen</td>
<td>Wilkosz</td>
<td>Deudon</td>
<td>Fauth</td>
<td>Keene</td>
<td>Hope</td>
<td>McShane</td>
<td>Hope</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>--------</td>
<td>------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------</td>
<td>---------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
<td>------</td>
<td>---------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DC</td>
<td>See 2</td>
<td>DC</td>
<td>DC</td>
<td>DC</td>
<td>DC</td>
<td>DC</td>
<td>CH</td>
<td>NR</td>
<td>CLIN</td>
<td>CLIN</td>
<td>CLIN</td>
<td>CLIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per, Cog</td>
<td>24</td>
<td>16 memory clinics in France, community dwelling</td>
<td>Per, Cog</td>
<td>5.5 yrs.</td>
<td>Ambulatory care setting, living in the community, USA</td>
<td>Inc</td>
<td>Nursing homes in 2 regions, France</td>
<td>Per</td>
<td>Old-age psychiatry services and a memory clinic, UK (3)</td>
<td>Per, Inc</td>
<td>See 5</td>
<td>Recruited through local general practitioners, community psychiatric nurses and consultant old-age psychiatrists, UK (5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>6</td>
<td>max 48</td>
<td>mean 10.1</td>
<td>6 yrs.</td>
<td>Until death, reported for 5 yrs.</td>
<td>mean: 25.8</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>max: 10 yrs.</td>
<td>max: 9 yrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>199</td>
<td>99</td>
<td>6</td>
<td>167</td>
<td>1 yr.</td>
<td>1 yr.</td>
<td>NR</td>
<td>3</td>
<td>1 or 2</td>
<td>1</td>
<td>30</td>
<td>mean:10.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.1</td>
<td></td>
<td>5</td>
<td>NR</td>
<td>32</td>
<td>30</td>
<td>NR</td>
<td>114</td>
<td>114</td>
<td>88</td>
<td>4</td>
<td>49</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD, VD, LBD, mixed</td>
<td>686</td>
<td>mean 5.1</td>
<td>6</td>
<td>7 at least 3 assessments</td>
<td>NR (n=88 followed until death)</td>
<td>NR (n=77 until death of which 75 &gt;1yr)</td>
<td>NR (SD 6.7)</td>
<td>NR (SD 8.8)</td>
<td>NR (n=88 followed until death)</td>
<td>NR (n=77 until death of which 75 &gt;1yr)</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td></td>
<td>207</td>
<td>6</td>
<td>13.3</td>
<td>99</td>
<td>30</td>
<td>4</td>
<td>121</td>
<td>69</td>
<td>49</td>
<td>48 (at least 1 yr.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>76.4</td>
<td></td>
<td>20.0 (10-26/30)</td>
<td>AD</td>
<td>Not reported</td>
<td>NR</td>
<td>NR</td>
<td>12.1</td>
<td>Not reported</td>
<td>13.3</td>
<td>NR</td>
<td>86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPI</td>
<td>INF</td>
<td>AD</td>
<td>NR</td>
<td>Not reported</td>
<td>NR (SD 6.7)</td>
<td>NR (SD 8.8)</td>
<td>86</td>
<td>79.6</td>
<td>79.7</td>
<td>NR (SD 6.7)</td>
<td>79.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INF</td>
<td></td>
<td>NPI</td>
<td>INF</td>
<td>OBS</td>
<td>INF</td>
<td>INF</td>
<td>INF</td>
<td>INF</td>
<td>INF</td>
<td>INF</td>
<td>INF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

| 19 | Deudon | 2009 | CH | Nursing homes in 2 regions, France | Per | 3 | 3 | 1 or 2 | 132 | 114 | 12.1 | Not reported | NR (SD 6.7) | 86 | CMAI, NPI and Observation Scale | INF | Agi, Irr, Psy, Hyperactivity (Wan, Ela, Irr) |
| 23 | Fauth | 2006 | NR | Community outreach and in-home respite programs (control group only), USA | Per | 3 | 4 | 1 | 85 | NR | 13.3 | Not reported | NR (SD 8.8) | 79.6 | Daily record of behaviour (DRB) | OBS | Dep, Agi/Wan, Irr, Sle, Total score |
| 6  | Ballard | 1996 | CLIN/DC | Old-age psychiatry services and a memory clinic, UK (3) | Per, Inc | 12 | 12 | 1 | 124 | 89 | NR | AD, VD, DLB | NR | 79.7 | Cornell scale | INF + PAR | Dep |
| 5  | Ballard | 1997 | CLIN/DC | See 3 | Per, Inc | 12 | 12 | 125 | 87 | NR | AD, VD, DLB | NR | 79.9 | Burn’s symptom checklist | NR | Pay |
| 35 | Keene | 1999 | CLIN | Recruited through local general practitioners, community psychiatric nurses and consultant old-age psychiatrists, UK (5) | Per | max: 10 yrs. | 30 | 4 | 99 | NR (n=88 followed until death) | NR | AD, VD | NR | PBE | INF | Irr |
| 31 | Hope | 2001 | CLIN | See 5 | Cog | max: 9 yrs. | mean:10.5 | 4 | 86 | NR (n=77 until death of which 75 >1yr) | NR | AD, VD | NR | PBE | INF | Wan |
| 44 | McShane | 1995 | CLIN | See 5 | Per, Cog | max: 5 yrs. (until death) | NR | 4 | 98 | 41 (who had died) | 13 | AD | NR | PBE | INF | Hal |
| 30 | Hope | 1999 | CLIN | See 5 | Per | max: 9 yrs. | NR | 4 | 100 | 48 (at least 1 yr.) | 14 | AD, VD, mixed, other | 60 | PBE and Past behavioural history | INF | Dep, Anx, Irr, Hal, Sle, Wan, Eat |
|   | McShane<sup>4</sup> | 1998 | CLIN | See 5 | Inc, Cog | max: 4 yrs. (until death) | NR | 4 | 86 | 80 (>4 yrs or until death) | 15 | AD, VD, DLB, Other | 77 | PBE | INF | Dep, Anx, Irr, Hal, Del |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|   | Asada<sup>4</sup> | 1999 | DC + VOL | Outpatients at clinic, voluntary patients whose caregivers were members of a self-help network and patients identified by formal service providers, Japan | Cog | 5 yrs. | 6 | 12 | 103 | 31 | NR | AD | NR (SD 8.7) | 79.4 | Troublesome behaviour scale (TBS) | INF | Agi/Irr factor, Wan factor |
| 47 | Neundorfer<sup>4</sup> | 2001 | DC | University hospitals, Alzheimer disease research centre, USA | Per | max: 5 yrs. | max: 10 | 12 | 353 | NR | NR | AD, other | 50 | 73 | CERAD | INF | Dep |
| 43 | McCarty<sup>4</sup> | 2000 | DC | Memory Disorders Clinic at University, USA | Cog | 24 | 3 | 12 | 150 | 61 | 13.52 | AD | 56 | 74.2 | Memory and Behaviour Problem Checklist-Revised | INF | Apa factor; Dep/Anx/Agi/Wan/Irr factor |
| 26 | Haupt<sup>4</sup> | 1996 | DC | Outpatient Clinic of University, Germany (4) | Cog | 24 | 3 | 12 | 90 | 61 | NR | AD | 57 | 74.3 | BEHAVE-AD | INF + PAR | Hal, Del |
| 27 | Haupt<sup>4</sup> | 2000 | DC | See 4 | Per, Inc | 24 | 3 | 12 | 90 | 60 | 13.5 | AD | 57 | 73.4 | BEHAVE-AD | INF + PAR | Dep, Anx, Irr, Agi/Wan, Hal, Del |
| 14 | Chang<sup>4</sup> | 2004 | DC | Memory clinic for veterans, Taiwan | Inc | mean: 51.9 | NR | NR | 56 | NR (>1 visit) | NR | AD | NR (SD 8.8) | 74.2 | SCID DSM III-R | INF + PAR | Dep, Hal, Del |

**Severe dementia (MMSE 0-9)**

|   | Wetzels<sup>4</sup> | 2010 | CH | Dementia special care units from nursing homes, The Netherlands | Per, Inc | 24 | 5 | 6 | 290 | 117 | 7.6 | AD, VD | NR (SD 7.4) | 81.7 | NPI nursing home version | INF | Apa, Dep, Anx, Irr, Agi/Wan, Hal, Del, Sie, Elb, Eat, Dis |
|   | Burgio<sup>4</sup> | 2007 | CH | Nursing homes, USA | Per, Cog | 18 | 4 | 6 | 78 | 55 | 8 | AD, VD, mixed, uncertain | 59.8 | 82.2 | Modified NHBPS and observation | INF + OBS | Irr |

|   | de Rooij<sup>4</sup> | 2012 | CH | 5 long-term care settings in The Netherlands and Belgium | Per | 12 | 3 | 6 | 179 | 126 | 5-MMSE 6.1 | Not reported | NR | 85.9 | QUALIDEM | INF | Dep, Agi |

**Normal cognitive function (MMSE 27+, no dementia)**

---

<sup>4</sup> Interview data from various studies covering different populations and methods.
| 37 | Kohler | 2010 | POP | Collaborative network of family practices, the Netherlands | Per, Inc, Cog | 6 | 3 | 3 | 598 | 412 | 27.7 | Not reported | 60 | 69.4 | Symptom Checklist | NR | Dep |
| 7 | Becker | 2009 | POP | Non-institutionalised individuals from the Part A Medicare list, USA | Cog | max: 9 yrs. | 9 | 12 | 441 | 288 (at least 3 measures) | NR (cognitively normal at baseline) | AD | 70 | 77.5 | CES-D | NR | Dep |
| 53 | Vinkers | 2004 | POP | Population-based study of all 85 year old inhabitants of city, The Netherlands | Cog | 4 yrs. | 5 | 12 | 500 | 298 | 27 | (MMSE<19 excluded) | Not reported | All aged 85 | 85 | GDS15 | NR | Dep |
| 3 | Amieva | 2008 | POP | Population-based sample of community dwelling individuals, France | Cog | max: 14 yrs. | 7 | 12-36 | 350 who developed AD and 350 control | 25 AD and 24 control | NR (100% / 90% "longitudinal data") | AD | 65 | 86.2 | CES-D | NR | Dep |
| 58 | Wilson | 2010 | POP | Census of a geographically defined region of city, USA | Cog | max: 8-9 yrs. | mean: 3.6/4.0 | 36 | 357+340 | NR (100% / 90% "longitudinal data") | Initially dementia free; 20.4 at dementia diagnosis | AD | 65 | 82.5 | CES-D (10-item) and Hamilton Depression Rating Scale (0-35) | INF + PAR | Dep |
| 9 | Bielak | 2011 | POP | Electoral role Australian citizens, Australia | Cog | max: 15 yrs. (mean: 6.0 yrs.) | 5 | 2-6yrs | 1,206 | NR | (without dementia) | Not reported | 70 | 78.16 | CES-D | PAR | Dep |
| 32 | Houde | 2008 | DC | Memory Clinic of university General Hospital, Canada | Cog | max: 10 yrs. (mean: 4.3 yrs.) | max: 11 | 1 | 60 | NR | 27.2 (MCI) | MCI, AD | 55 | 74.5 | GDS | NR | Dep |
| 21 | Dotson | 2008 | VOL | Community dwelling generally healthy group of volunteers, USA | Cog | max: 26 yrs. (mean: 4.4 yrs.) | NR | 24 | 1,586 | NR | 28.65 (without dementia) | Not reported | 50 | 65.4 | CES-D | PAR | Dep |
| 41 | Mackin | 2011 | VOL | Alzheimer's Disease Neuroimaging Initiative, USA and Canada | Per, Cog | 3 yrs. | 4 | 12 | 405 | 227 | 27.2 (MCI) | MCI | NR | 74.9 | GDS | NR | Dep |
| 57 | Wilson | 2008 | OTHER | Older Catholic nuns, priests and brothers, USA | Cog | max: 13 yrs. | mean: 7.8 | 24 | 917 | 23 (13yrs; 5+yrs: 630) | 27.4 No dementia at baseline, some developed | MCI, AD | 65 | 74.8 | CES-D | PAR | Dep |
### Comparing cognitive groups

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Janzing</td>
<td>2000</td>
<td>CH</td>
<td>6 homes for the elderly in the specified region, The Netherlands</td>
<td>12 yrs.</td>
<td>3 months</td>
<td>12 months</td>
<td>201 (49 dem)</td>
<td>18.2 (moderate dementia) and 26.7 (normal)</td>
<td>Not reported</td>
<td>NR (SD 5.3; 6.5)</td>
<td>86.6 (moderate dementia); 82.6 (normal)</td>
</tr>
<tr>
<td>Blansi</td>
<td>2005</td>
<td>DC</td>
<td>Memory Clinic of University Hospital and control sample, Switzerland</td>
<td>max: 3-4 yrs.</td>
<td>3-4 years</td>
<td>12 years</td>
<td>662 (217 dem)</td>
<td>26.1 (AD, 24+); 28.8 (control)</td>
<td>AD</td>
<td>50</td>
<td>73.4</td>
</tr>
<tr>
<td>Li</td>
<td>2001</td>
<td>DC + VOL</td>
<td>Cognitively impaired outpatients and cognitively normal volunteers, USA (76% treated with antidepressant medication)</td>
<td>max: 7.8 yrs. (mean 3.5 yrs.)</td>
<td>NR</td>
<td>7+ years</td>
<td>294 (129 dem)</td>
<td>17 (moderate dementia); 29 (normal); 26.1 (MCI)</td>
<td>MCI, AD, VAD</td>
<td>50</td>
<td>76.5</td>
</tr>
<tr>
<td>Bunce</td>
<td>2012</td>
<td>PB</td>
<td>Aged 70 and over living in the community in Canberra or nearby, Australia</td>
<td>max: 12 yrs.</td>
<td>max 4 yrs.</td>
<td>4 years</td>
<td>837-870</td>
<td>95</td>
<td>Not reported</td>
<td>70</td>
<td>76.6</td>
</tr>
</tbody>
</table>

### Dementia severity not reported

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>King-Kallimanis</td>
<td>2010</td>
<td>CH</td>
<td>Veterans Administration nursing homes, USA</td>
<td>4 yrs. (mean 390/297 days)</td>
<td>mean:4</td>
<td>3</td>
<td>6,673</td>
<td>NR</td>
<td>NR</td>
<td>Not reported</td>
<td>24</td>
</tr>
<tr>
<td>Volicer</td>
<td>2012</td>
<td>CH</td>
<td>8 nursing homes, The Netherlands (retrospective Minimum Dataset analysis)</td>
<td>15</td>
<td>4</td>
<td>3</td>
<td>1101</td>
<td>NR</td>
<td>AD, other, mixed</td>
<td>65</td>
<td>84.2</td>
</tr>
<tr>
<td>Morgan; Kunik</td>
<td>2012</td>
<td>DC</td>
<td>Veterans administration outpatient data files, flyers, radio and print advertisements and the primary care and geriatrics clinic (94% male), USA</td>
<td>24</td>
<td>7</td>
<td>4</td>
<td>171</td>
<td>NR</td>
<td>NR</td>
<td>Not reported</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Cohen-Mansfield</td>
<td>1998</td>
<td>CH?</td>
<td>Community dwelling, senior day care centres in Maryland, USA</td>
<td>Per, Cog</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>200</td>
<td>104</td>
<td>NR</td>
</tr>
<tr>
<td>---</td>
<td>-----------------</td>
<td>------</td>
<td>-----</td>
<td>----------------------------------------------------------</td>
<td>---------</td>
<td>----</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>-----</td>
<td>----</td>
</tr>
<tr>
<td>15</td>
<td>Chen</td>
<td>1991</td>
<td>DC</td>
<td>Patients presenting for evaluation of dementia in a clinical practice, USA</td>
<td>Inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Jost</td>
<td>1996</td>
<td>DC</td>
<td>Autopsy confirmed AD patients enrolled in a regional brain bank through a university geropsychiatry clinic and by clinicians and caregivers in surrounding communities, USA</td>
<td>Inc</td>
<td>Retrospective using medical records</td>
<td>Retrospective</td>
<td>Retrospective</td>
<td>100</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>42</td>
<td>Marin</td>
<td>1997</td>
<td>DC</td>
<td>Alzheimer's disease Research Centre, USA</td>
<td>Cog</td>
<td>mean 37.1</td>
<td>mean:6.0</td>
<td>6</td>
<td>201</td>
<td>153 (12+ months)</td>
<td>NR</td>
</tr>
<tr>
<td>13</td>
<td>Caligiuri</td>
<td>2003</td>
<td>NR</td>
<td>NR, USA</td>
<td>Inc</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>S4</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>
Reference numbers refer to the Online Reference List

**Papers from the same study groups:**
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece)
2 Maasbed study
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol)
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich)
5 Hope et al. (Oxford)

**Reports on:**
- Per=Persistence
- Inc=Incidence
- Cog=Association with cognitive function

**Settings**
- DC=Dementia or memory clinic
- POP=Population-based
- CH=Care home
- CLIN=Referred by clinicians
- VOL=Volunteers
- NR=Not reported

**Data collection**
- INF=Informant-based
- PAR=Participant-based
- OBS=Observation

**BPSD= behavioural and psychological symptoms of dementia**
- Apa=apathy
- Dep=depression
- Anx=anxiety
- Irr=irritability/aggression
- Agi=agitation
- Hal=hallucination
- Per=persecution
- Mis=misidentification
- Sle=sleep problems
- Wan=wandering
- Ela=elation

**AD=Alzheimer’s disease**
**VD=Vascular Dementia**
**DLB=Dementia with Lewy Bodies**
**MCI=Mild Cognitive Impairment**
**PD=Parkinson’s Disease**
**NR=not reported**
**MMSE=Mini Mental State Examination**
### Table DS2  Definition and baseline prevalence of BPSD

#### Affective symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Depression / Anxiety / Apathy</th>
<th>Definition</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 Clare</td>
<td>2012</td>
<td>HADS; NPI total</td>
<td>Dep: 8 items including a loss of interest, laughing less, being less cheerful, being less optimism, and not being hopeful about the future Anx: 8 items including about feeling tense, worrying, panic attacks, feeling something awful is about to happen</td>
<td></td>
<td>NR</td>
</tr>
<tr>
<td>22 Eustace</td>
<td>2002</td>
<td>BEHAVE-AD</td>
<td>Dep: Tearfulness and other depressed mood (e.g. death statements) with or without clear affective or physical components Anx: Anxiety about upcoming events, other anxieties, fear of being left alone, other phobias</td>
<td>Dep: 33 Anx: 52</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Berger</td>
<td>2005</td>
<td>BEHAVE-AD</td>
<td>Dep: Tearfulness and other depressed mood (e.g. death statements) with or without clear affective or physical components Anx: Anxiety about upcoming events, other anxieties, fear of being left alone, other phobias</td>
<td>Dep median 0.5 Anx median 0.0</td>
<td></td>
</tr>
<tr>
<td>39 Levy</td>
<td>1996</td>
<td>ADAS</td>
<td>Dep: Tearfulness and depression</td>
<td>Dep: 23</td>
<td></td>
</tr>
<tr>
<td>29 Holtzer</td>
<td>2005</td>
<td>CUSPAD</td>
<td>Dep: Depressed mood (sad, depressed, blue, down in the dumps), difficulty sleeping and change in appetite</td>
<td>Dep: 40</td>
<td></td>
</tr>
<tr>
<td>50 Scarmeas</td>
<td>2002</td>
<td>CUSPAD</td>
<td>Dep: Depressed mood (sad, depressed, blue, down in the dumps), difficulty sleeping and change in appetite</td>
<td>Dep: 43.7</td>
<td></td>
</tr>
<tr>
<td>20 Devanand</td>
<td>1997</td>
<td>CUSPAD</td>
<td>Dep: Depressed mood (sad, depressed, blue, down in the dumps), difficulty sleeping and change in appetite</td>
<td>Dep: 25.1</td>
<td></td>
</tr>
<tr>
<td>24 Garre-Olmo</td>
<td>2010</td>
<td>NPI-10</td>
<td>Dep: Includes seeming sad or depressed, saying or acting as if sad or in low spirits Anx: Includes being very nervous, being worried, or frightened, being tense Apa: Loss of interest, more difficult to engage, apathetic or indifferent</td>
<td>Dep: 43.8 Anx: 31.2 Apa: 51.3</td>
<td></td>
</tr>
<tr>
<td>1 Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Dep: Includes seeming sad or depressed, saying or acting as if sad or in low spirits Anx: Includes being very nervous, being worried, or frightened, being tense Apa: Loss of interest, more difficult to engage, apathetic or indifferent</td>
<td>Dep: 35.2 Anx: 21.1 Apa: 40.2</td>
<td></td>
</tr>
<tr>
<td>2 Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Mood/apathy cluster: depression, apathy, night-time behaviour disturbances and eating abnormalities (See Aalten)</td>
<td>See Aalten</td>
<td></td>
</tr>
<tr>
<td>25 Gillette-Guyonnet</td>
<td>2011</td>
<td>NPI</td>
<td>Dep: Includes seeming sad or depressed, saying or acting as if sad or in low spirits Anx: Includes being very nervous, being worried, or frightened, being tense Apa: Loss of interest, more difficult to engage, apathetic or indifferent</td>
<td>Dep: 20.6 Anx: 23.9 Apa: 43.0</td>
<td></td>
</tr>
<tr>
<td>59 Zahodne</td>
<td>2013</td>
<td>CUSPAD</td>
<td>Dep: Depressed mood (sad, depressed, blue, down in the dumps), difficulty sleeping and change in appetite</td>
<td>Mean 0.74 (0-4)</td>
<td></td>
</tr>
<tr>
<td><strong>Moderately severe dementia (MMSE 10-14)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23 Fauth</td>
<td>2006</td>
<td>Daily record of behaviour (DRB)</td>
<td>Dep: Mood, include crying and being tearful</td>
<td></td>
<td>NR</td>
</tr>
<tr>
<td>6 Ballard</td>
<td>1996</td>
<td>Cornell scale</td>
<td>Dep: Sadness, sad expression, sad voice, tearfulness, lack of reactivity to pleasant events</td>
<td>Dep: minor 23.6; major 23.6</td>
<td></td>
</tr>
<tr>
<td>30 Hope</td>
<td>1999</td>
<td>PBE and Past behavioural history interview</td>
<td>Dep: Apparent sadness, appearing to be particularly sad, miserable or depressed Anx: Anxiety or fearfulness (with physical symptoms)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>45 McShane</td>
<td>1998</td>
<td>PBE</td>
<td>Dep: Apparent sadness, appearing to be particularly sad, miserable or depressed Anx: Anxiety or fearfulness (with physical symptoms)</td>
<td>Dep: 27.9 Anx: 16.3</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Author</td>
<td>Year</td>
<td>Scale/Patient Type</td>
<td>Dep</td>
<td>Notes</td>
</tr>
<tr>
<td>----</td>
<td>----------</td>
<td>------</td>
<td>--------------------</td>
<td>-----</td>
<td>-------</td>
</tr>
<tr>
<td>47</td>
<td>Neundorfer</td>
<td>2001</td>
<td>CERAD</td>
<td><strong>Dep</strong>: Feelings of anxiety, sad appearance, hopelessness, crying, feelings of guilt, poor self-esteem and feelings that life is not worth living</td>
<td>NR</td>
</tr>
<tr>
<td>43</td>
<td>McCarty</td>
<td>2000</td>
<td>Memory and Behaviour Problem Checklist-Revised</td>
<td><strong>Apathy cluster</strong>: forgetting the day, can’t self-start activities, unable to keep busy, following people, spends time inactive, talking little or none, sad/depressed</td>
<td>mean 1.34 (0.66) of max 3.00</td>
</tr>
<tr>
<td>27</td>
<td>Haupt*</td>
<td>2000</td>
<td>BEHAVE-AD</td>
<td><strong>Dep</strong>: Tearfulness and other depressed mood (e.g. death statements) with or without clear affective or physical components</td>
<td><strong>Anx</strong>: Anxiety about upcoming events, other anxieties, fear of being left alone, other phobias</td>
</tr>
<tr>
<td>14</td>
<td>Chang</td>
<td>2004</td>
<td>SCID DSM IIIR</td>
<td><strong>Dep</strong>: SCID diagnosis</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>NPI nursing home version</td>
<td><strong>Dep</strong>: Includes seeming sad or depressed, saying or acting as if sad or in low spirits</td>
<td><strong>Anx</strong>: Includes being very nervous, being worried, or frightened, being tense</td>
</tr>
<tr>
<td>18</td>
<td>de Rooij</td>
<td>2012</td>
<td>QUALIDEM</td>
<td><strong>Dep</strong>: negative affect</td>
<td>NR</td>
</tr>
<tr>
<td>37</td>
<td>Kohler</td>
<td>2010</td>
<td>Symptom Checklist</td>
<td><strong>Dep</strong>: As in Symptom Checklist</td>
<td>Dep: 22 scored high</td>
</tr>
<tr>
<td>7</td>
<td>Becker</td>
<td>2009</td>
<td>CES-D</td>
<td><strong>Dep</strong>: Includes depressed affect, positive affect, somatic complaint, interpersonal problem</td>
<td>NR</td>
</tr>
<tr>
<td>53</td>
<td>Vinkers</td>
<td>2004</td>
<td>GDS15</td>
<td><strong>Dep</strong>: Satisfaction with life, dropping activities and interests, feeling life is empty, being bored, not being hopeful about future, being bothered by thoughts, not being in good spirits, being afraid, feeling less happy, feeling helpless, being restless, not going out, worrying, memory problems, feeling downhearted and blue, feeling worthless, being less excited, having less energy, feeling upset, crying, difficulty concentrating, not enjoying getting up, avoiding social gathering, being less decisive, not having a clear mind</td>
<td>Dep: Median score: 2, score 2 or less: 67%</td>
</tr>
<tr>
<td>3</td>
<td>Amieva</td>
<td>2008</td>
<td>CES-D</td>
<td><strong>Dep</strong>: Includes depressed affect, positive affect, somatic complaint, interpersonal problem</td>
<td>NR</td>
</tr>
<tr>
<td>58</td>
<td>Wilson</td>
<td>2010</td>
<td>CES-D (10-item) and Hamilton Depression Rating Scale (0-35)</td>
<td><strong>Dep</strong>: Includes depressed affect, positive affect, somatic complaint, interpersonal problem (CES-D) and depression, anxiety, insomnia, somatic complaint (HDRS)</td>
<td>Dep: Median CES-D score: 1.0; median HDRS score 2.0</td>
</tr>
<tr>
<td>9</td>
<td>Bielak</td>
<td>2011</td>
<td>CES-D</td>
<td><strong>Dep</strong>: Includes depressed affect, positive affect, somatic complaint, interpersonal problem</td>
<td>Mean 50.1</td>
</tr>
<tr>
<td>32</td>
<td>Houde</td>
<td>2008</td>
<td>GDS</td>
<td><strong>Dep</strong>: Satisfaction with life, dropping activities and interests, feeling life is empty, being bored, not being hopeful about future, being bothered by thoughts, not being in good spirits, being afraid, feeling less happy, feeling helpless, being restless, not going out, worrying, memory problems, feeling downhearted and blue, feeling worthless, being less excited, having less energy, feeling upset, crying, difficulty concentrating, not enjoying getting up, avoiding social gathering, being less decisive, not having a clear mind</td>
<td>Dep: 52</td>
</tr>
<tr>
<td>21</td>
<td>Dotson</td>
<td>2008</td>
<td>CES-D</td>
<td><strong>Dep</strong>: Includes depressed affect, positive affect, somatic complaint, interpersonal problems</td>
<td>NR</td>
</tr>
</tbody>
</table>
Mackin, 2011, GDS, Dep: Satisfaction with life, dropping activities and interests, feeling life is empty, being bored, not being hopeful about future, being bothered by thoughts, not being in good spirits, being afraid, feeling less happy, feeling helpless, being restless, not going out, worrying, memory problems, feeling downhearted and blue, feeling worthless, being less excited, having less energy, feeling upset, crying, difficulty concentrating, not enjoying getting up, avoiding social gathering, being less decisive, not having a clear mind. Dep: 55

Wilson, 2008, CES-D, Dep: Includes depressed affect, positive affect, somatic complaint, interpersonal problems. Dep: 23.9 reporting 1, 9.7 reporting 2, 6.1 reporting 3 and 6.8 reporting 4 or more

Comparing cognitive groups

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Dep:</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janzing</td>
<td>2000</td>
<td>GMS AGECAT</td>
<td>Subcase or depressive case</td>
<td></td>
</tr>
<tr>
<td>Blansi</td>
<td>2005</td>
<td>NOSGER</td>
<td>Mood</td>
<td></td>
</tr>
<tr>
<td>Li</td>
<td>2001</td>
<td>HDRS</td>
<td>HDRS&gt;7 and “motivationally related depressive symptoms”, including loss of interest, fatigue, retardation, loss of energy and general somatic symptoms</td>
<td></td>
</tr>
<tr>
<td>Bunce</td>
<td>2012</td>
<td>Goldberg depression and anxiety scale</td>
<td>9 items including about energy, interest, confidence, hope, concentration, slowing, weight and waking</td>
<td></td>
</tr>
</tbody>
</table>

Dementia severity not reported

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Dep:</th>
<th>Anx:</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jost</td>
<td>1996</td>
<td>Medical record review</td>
<td>Depression, mood change, social withdrawal, suicidal ideation (reported as separate symptoms)</td>
<td>Anxiety</td>
<td></td>
</tr>
<tr>
<td>Marin</td>
<td>1997</td>
<td>ADAS</td>
<td>tearfulness, depressed mood</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Psychotic symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eustace</td>
<td>2002</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one’s house is not one’s home, spouse or caregiver is imposter, abandonment, other)</td>
</tr>
<tr>
<td>Levy</td>
<td>1996</td>
<td>ADAS</td>
<td>Psy: Hallucination (visual, auditory, tactile) and delusion (belief in ideas that are almost certainly not true) combined in psychosis subscale</td>
</tr>
<tr>
<td>Berger</td>
<td>2005</td>
<td>BEHAVE-AD</td>
<td>Psy symptoms cluster, Del: Paranoid and delusional ideation (people are stealing things, one’s house is not one’s home, spouse or caregiver is imposter, abandonment, other) Hal: Visual, auditory, olfactory and other hallucinations</td>
</tr>
</tbody>
</table>

Mild dementia (MMSE 21-26)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eustace</td>
<td>2002</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one’s house is not one’s home, spouse or caregiver is imposter, abandonment, other)</td>
</tr>
</tbody>
</table>

Moderate dementia (MMSE 15-20)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levy</td>
<td>1996</td>
<td>ADAS</td>
<td>Psy: Hallucination (visual, auditory, tactile) and delusion (belief in ideas that are almost certainly not true) combined in psychosis subscale</td>
</tr>
<tr>
<td>Berger</td>
<td>2005</td>
<td>BEHAVE-AD</td>
<td>Psy symptoms cluster, Del: Paranoid and delusional ideation (people are stealing things, one’s house is not one’s home, spouse or caregiver is imposter, abandonment, other) Hal: Visual, auditory, olfactory and other hallucinations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eustace</td>
<td>2002</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one’s house is not one’s home, spouse or caregiver is imposter, abandonment, other) Hal: Visual, auditory, olfactory and other hallucinations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levy</td>
<td>1996</td>
<td>ADAS</td>
<td>Psy: Hallucination (visual, auditory, tactile) and delusion (belief in ideas that are almost certainly not true) combined in psychosis subscale</td>
</tr>
<tr>
<td>Berger</td>
<td>2005</td>
<td>BEHAVE-AD</td>
<td>Psy symptoms cluster, Del: Paranoid and delusional ideation (people are stealing things, one’s house is not one’s home, spouse or caregiver is imposter, abandonment, other) Hal: Visual, auditory, olfactory and other hallucinations</td>
</tr>
</tbody>
</table>

12
<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Year</th>
<th>Study</th>
<th>Hallucinations</th>
<th>Delusions</th>
<th>Report Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scarmeas</td>
<td>2002</td>
<td>CUSPAD</td>
<td>Hal: Auditory, visual, tactile and olfactory illusions Del: General del (strange ideas or unusual beliefs), paranoid del (people are stealing things or unfaithful wife/husband or unfounded suspicions), abandonment del (accused caregiver of plotting to leave him/her), somatic del (false belief that the patient has cancer or other physical illness), misidentification (false belief that people are in the house when nobody is there, or that someone else is in the mirror, or that spouse/caregiver is an imposter, or that the patient's home is not home, or that the characters on TV are real) and a miscellaneous category. At least one of these.</td>
<td>Del: 33.3 Hal: 11.5</td>
<td></td>
</tr>
<tr>
<td>Devanan</td>
<td>1997</td>
<td>CUSPAD</td>
<td>Hal: Auditory, visual, tactile and olfactory Del: Paranoid del, misidentification (reported also separately), somatic and abandonment</td>
<td>Del: 23.9 Hal: 8.1</td>
<td></td>
</tr>
<tr>
<td>Holtzer</td>
<td>2003</td>
<td>CUSPAD</td>
<td>Hal: Auditory, visual, tactile and olfactory Del: Paranoid del, misidentification (reported also separately), somatic and abandonment</td>
<td>Del: 40 Hal: 8</td>
<td></td>
</tr>
<tr>
<td>Garre-Olmo</td>
<td>2010</td>
<td>NPI-10</td>
<td>Hal: Including visions, voices, experiencing things that are not present Del: Beliefs that are not true, believing people are not who they say they are, believing their house is their home</td>
<td>Del: 16.1 Hal: 5.5</td>
<td></td>
</tr>
<tr>
<td>Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Hal: Including visions, voices, experiencing things that are not present Del: Beliefs that are not true, believing people are not who they say they are, believing their house is their home</td>
<td>Del: 21.6 Hal: 9.5</td>
<td></td>
</tr>
<tr>
<td>Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Psychosis cluster: Hallucinations and delusion (See Aalten)</td>
<td>See Aalten</td>
<td></td>
</tr>
<tr>
<td>Gillette-Guyonnet</td>
<td>2011</td>
<td>NPI</td>
<td>Hal: Including visions, voices, experiencing things that are not present Del: Beliefs that are not true, believing people are not who they say they are, believing their house is their home</td>
<td>Del: 9.3 Hal: 3.1</td>
<td></td>
</tr>
<tr>
<td>Rosen</td>
<td>1991</td>
<td>DSMIII</td>
<td>Hal: e.g. visual, auditory, olfactory Del: Various types e.g. paranoia, the belief that one's spouse is an impostor</td>
<td>Del: 34.4 Hal: 31.3</td>
<td></td>
</tr>
<tr>
<td>Paulsen</td>
<td>2000</td>
<td>DIS for DSMIII</td>
<td>Hal: e.g. visual, auditory, olfactory Del: Various types e.g. paranoia, the belief that one's spouse is an impostor</td>
<td>Psy: 23</td>
<td></td>
</tr>
<tr>
<td>Wilkosz</td>
<td>2006</td>
<td>CERAD</td>
<td>Hal: Sensory perceptions for which there was no basis in reality Del: A persistent false belief based on incorrect inference about external reality, resistant to persuasion or contrary evidence, and not attributable to social or cultural mores</td>
<td>Del: 0 Hal: 0 (excluded those with symptoms at baseline)</td>
<td></td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Year</th>
<th>Study</th>
<th>Hallucinations</th>
<th>Delusions</th>
<th>Report Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deudon</td>
<td>2009</td>
<td>CMAI; NPI and Observation Scale</td>
<td>NPI Psychotic subgroup: Hal (Including visions, voices, experiencing things that are not present) and del (beliefs that are not true, believing people are not who they say they are, believing their house is their home)</td>
<td>mean 6.14 (severity x frequency of 2 symptoms)</td>
<td></td>
</tr>
<tr>
<td>Ballard</td>
<td>1997</td>
<td>Burn's symptom checklist</td>
<td>Hal: If described by the patient or if clearly described to the informant by the patient Del: Beliefs that are false, firmly held and impervious to evidence to the contrary and that are not explained entirely by cognitive failure and that have been experienced at least twice, on occasions more than 1 week apart Mis: Included the categories of Capgras delusions, misidentification of house, misidentification of television, and misidentification of one's mirror image. Symptoms also had to fulfil the definition for a delusion</td>
<td>Psy: 65.0</td>
<td></td>
</tr>
<tr>
<td>McShane</td>
<td>1995</td>
<td>PBE</td>
<td>Hal: Appears to have auditory or visual hallucinations</td>
<td>NR (31.7 at some point during the study)</td>
<td></td>
</tr>
<tr>
<td>Hope</td>
<td>1999</td>
<td>PBE and Past behavioural history interview</td>
<td>Hal: Appears to have auditory or visual hallucinations Del: Persecutory ideas: expressed ideas that people were trying to harm him/her, plotting against him/her or stealing or damaging his/her property</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>McShane</td>
<td>1998</td>
<td>PBE</td>
<td>Hal: Appears to have auditory or visual hallucinations Del: Persecutory ideas: expressed ideas that people were trying to harm him/her, plotting against him/her or stealing or damaging his/her property</td>
<td>Del: 11.6, Hal: 8.1</td>
<td></td>
</tr>
<tr>
<td>Haupt</td>
<td>1996</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things,</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GDS**

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Year</th>
<th>Study</th>
<th>Hallucinations</th>
<th>Delusions</th>
<th>Report Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td>NR (31.7 at some point during the study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Del: GDS 5: 48; GDS 6: 25; GDS 7: 14 Hal: GDS 5: 12;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Instrument</td>
<td>Irritability / Agitation / Wandering</td>
<td>Prevalence (%)</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>Haupt</td>
<td>2000</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one's house is not one's home, spouse or caregiver is imposter, abandonment, other)</td>
<td>GDS 6: 25; GDS 7: 19</td>
<td></td>
</tr>
<tr>
<td>Chang</td>
<td>2004</td>
<td>SCID DSM III-R</td>
<td>Hal: Formed visual hallucinations, non-formed visual hallucinations, auditory hallucinations or other hallucinations (olfactory or tactile) Del: Thoughts or experiences of systematic persecution, non-systematic persecution, theft, infidelity or jealousy</td>
<td>Del: 35 Hal: 18</td>
<td></td>
</tr>
<tr>
<td>Haupt</td>
<td>2000</td>
<td>BEHAVE-AD</td>
<td>Hal: Including visions, voices, experiencing things that are not present Del: Beliefs that are not true, believing people are not who they say they are, believing their house is their home</td>
<td>Del: 0 Hal: 0 Excluded</td>
<td></td>
</tr>
</tbody>
</table>

### Severe dementia (MMSE 0-9)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Hallucinations, paranoia, accusatory behaviour, and delusions (reported as separate symptoms)</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haupt</td>
<td>2000</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one's house is not one's home, spouse or caregiver is imposter, abandonment, other)</td>
<td>GDS 6: 25; GDS 7: 19</td>
</tr>
</tbody>
</table>

### Dementia severity not reported

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Hallucinations, paranoia, accusatory behaviour, and delusions (reported as separate symptoms)</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haupt</td>
<td>2000</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one's house is not one's home, spouse or caregiver is imposter, abandonment, other)</td>
<td>GDS 6: 25; GDS 7: 19</td>
</tr>
</tbody>
</table>

### Hyperactivity symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Irritability / Agitation / Wandering</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lev</td>
<td>1991</td>
<td>DSM III-R</td>
<td>Psy: presence of persistent hallucinations, illusions or delusions</td>
<td></td>
</tr>
<tr>
<td>Jost</td>
<td>1996</td>
<td>Medical record review</td>
<td>Hallucinations, paranoia, accusatory behaviour, and delusions (reported as separate symptoms)</td>
<td>NR</td>
</tr>
<tr>
<td>Marin</td>
<td>1997</td>
<td>ADAS</td>
<td>Hal: visual, auditory, tactile hallucination Del: belief in ideas that are almost certainly not true</td>
<td>Del: moderate/severe: 4. very mild or greater: 13 Hal: moderate/severe: 1, very mild or greater: 7</td>
</tr>
<tr>
<td>Caligiuri</td>
<td>2003</td>
<td>BEHAVE-AD</td>
<td>Hal: Visual, auditory, olfactory and other hallucinations Del: Paranoid and delusional ideation (people are stealing things, one's house is not one's home, spouse or caregiver is imposter, abandonment, other)</td>
<td>Del: 0 Hal: 0 Excluded</td>
</tr>
</tbody>
</table>

### Irritability / Agitation / Wandering

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Definition</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eustace</td>
<td>2002</td>
<td>BEHAVE-AD</td>
<td>Irr: Verbal outbursts, physical threats and/or violence, other agitation Agi/Wan: activity disturbance, includes wandering and purposeless and inappropriate activities</td>
<td>Irr: 42 Agi/Wan: 58</td>
</tr>
<tr>
<td>Levy</td>
<td>1996</td>
<td>ADAS</td>
<td>Agi/Wan: Pacing and increased motor activity</td>
<td>Agi/Wan: 25</td>
</tr>
<tr>
<td>Berger</td>
<td>2005</td>
<td>BEHAVE-AD</td>
<td>Behavioural disturbances cluster - aggressiveness, activity disturbances</td>
<td>Median 1.0</td>
</tr>
<tr>
<td>Scarmeas</td>
<td>2007</td>
<td>CUSPAD</td>
<td>Agi/Wan: Agitation/restlessness Wan: Wandering away from home or from the caregiver Irr: Verbal outbursts, physical threats, violence</td>
<td>NR</td>
</tr>
<tr>
<td>Devanaan</td>
<td>1997</td>
<td>CUSPAD</td>
<td>Agi/Wan: Agitation/restlessness Irr: Verbal outbursts, physical threats, violence</td>
<td>Agi/Wan: 38.7 Irr (physical aggression): 6.4%</td>
</tr>
<tr>
<td>Garre-Olmo</td>
<td>2010</td>
<td>NPI-10</td>
<td>Agi/Wan: Includes pacing, repetitive behaviour Irr (&quot;irritability&quot;): Includes getting irritated and easily disturbed; changeable moods, abnormally impatient; Irr (&quot;agitation&quot;) refuses to cooperate or won’t let people help</td>
<td>Agi/Wan: 18.9 Irr: 36.7; 23</td>
</tr>
<tr>
<td>Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Agi/Wan: Includes pacing, repetitive behaviour Irr (&quot;irritability&quot;): Includes getting irritated and easily disturbed; changeable moods, abnormally impatient; Irr (&quot;agitation&quot;) refuses to cooperate or won’t let people help</td>
<td>Agi/Wan: 25.6 Irr: 23.6; 18.6</td>
</tr>
<tr>
<td>NPI Hyperactivity cluster: agitation, euphoria, irritability, disinhibition, aberrant motor behaviour.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPI Hyperactivity cluster: agitation, euphoria, irritability, disinhibition, aberrant motor behaviour.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>See 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPI Hyperactivity cluster: agitation, euphoria, irritability, disinhibition, aberrant motor behaviour.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPI Hyperactivity subgroup: Includes agi/wan (pacing, repetitive behaviour) and irr (anger, uncooperative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.2 Irr: 20.6; 21.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderately severe dementia (MMSE 10-14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Deudon</td>
<td>2009</td>
<td>CMAI, NPI and Observation Scale</td>
<td>Agi/Wan: Restless, pacing up and down</td>
</tr>
<tr>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Keene</td>
<td>1999</td>
<td>PBE</td>
<td>Irr: Physical aggression (e.g. hitting, kicking, scratching, pushing or spitting in an aggressive manner), aggressive resistance (resisting help or being uncooperative), physical threats (e.g. shaking a fist), verbal aggression (spoken in an aggressive or angry way, e.g. angry or cross tone or voice raised in anger), refusing to speak (wilful or uncooperative), destructive behaviour (damaged objects in anger or deliberately), general irritability (bad mood or likely to become irritable at the least provocation), avoiding aggressive behaviour (carer avoided something that might have resulted in aggressive behaviour)</td>
</tr>
<tr>
<td>Verbal aggression: 89; aggressive resistance: 71; physical aggression: 51; physical threats: 48; refusing to speak: 44; destructive behaviour: 25; general irritability: 39; avoiding aggressive behaviour: 89</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Hope</td>
<td>2001</td>
<td>PBE</td>
<td>Wan: Increased walking, walks distinctly more than normal; attempting to leave home, made attempts to leave the house that have been prevented; being brought back home, number of times being brought back home; trailing, tends to follow right behind carer for total of at least 30 minutes; aimless walking, walked about the house, garden or beyond without an obvious reason; pottering, tended to walk around the house trying to do household chores or potter around the garden trying to do odd jobs; inappropriate, walking around the house, garden or outside for a reason that seems odd to carer; excessive inappropriate, walked around the house, garden or outside for an appropriate reason but repeated this several times; night time walking, walked during the night, includes walking aimlessly, pottering and walking inappropriately or excessively</td>
</tr>
<tr>
<td>Increased walking: 16; Attempting to leave home: 10; Being brought back home: 13; Trailing: 21; Aimless walking: 21; Pottering: 19; Inappropriate or excessive appropriate: 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Hope</td>
<td>1999</td>
<td>PBE and Past behavioural history interview</td>
<td>Wan: Time spent walking; attempts to leave house; being brought back; trailing and checking; aimless walking Irr: Physical aggression towards others; aggressive resistance (i.e. resisting care during intimate care e.g. washing and dressing), verbal aggression (i.e. spoke in an aggressive or angry way)</td>
</tr>
<tr>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>McShane</td>
<td>1998</td>
<td>PBE</td>
<td>Irr: Verbal aggression (i.e. spoke in an aggressive or angry way)</td>
</tr>
<tr>
<td>Irr: 43</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Asada</td>
<td>1999</td>
<td>Troublesome behaviour scale (TBS)</td>
<td>Irritability factor: false accusation, ill-natured denial and/or distortion, hiding and/or losing things, interfering with a happy home circle, being restless and/or noisy at night, physical and/or verbal aggression, repetition and/or clinging, pica. Hyperactivity factor: hiding and/or losing things, wandering, pica, rummaging, making the dwelling dirty, crying and/or screaming</td>
</tr>
<tr>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Instrument</td>
<td>Definition</td>
<td>Prevalence (%)</td>
</tr>
<tr>
<td>-----------------</td>
<td>------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Garre-Olmo</td>
<td>2010</td>
<td>NPI-10</td>
<td>Too cheerful or too happy, abnormally good mood, finds humour where others do not</td>
<td>9</td>
</tr>
<tr>
<td>Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Too cheerful or too happy, abnormally good mood, finds humour where others do not</td>
<td>3.5</td>
</tr>
<tr>
<td>Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Too cheerful or too happy, abnormally good mood, finds humour where others do not</td>
<td>3.5</td>
</tr>
</tbody>
</table>
### Sleep problems

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Sleep problems</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 Eustace</td>
<td>2002</td>
<td>BEHAVE-AD</td>
<td>Diurnal rhythm disturbances</td>
<td>21</td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Berger</td>
<td>2005</td>
<td>BEHAVE-AD</td>
<td>Diurnal rhythm disturbance</td>
<td>Median 0.0</td>
</tr>
<tr>
<td>1 Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Difficulty sleeping, up at night, wander at night</td>
<td>13.1</td>
</tr>
<tr>
<td>2 Aalten</td>
<td>2005</td>
<td>NPI</td>
<td>Difficulty sleeping, up at night, wander at night</td>
<td></td>
</tr>
<tr>
<td>25 Gillette-Guyonnet</td>
<td>2011</td>
<td>NPI</td>
<td>Difficulty sleeping, up at night, wander at night</td>
<td>11.5</td>
</tr>
<tr>
<td><strong>Moderately severe dementia (MMSE 10-14)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23 Fauth</td>
<td>2006</td>
<td>Daily record of behaviour (DRB)</td>
<td>Woke caregiver up during the night</td>
<td>NR</td>
</tr>
<tr>
<td>30 Hope</td>
<td>1999</td>
<td>PBE and Past behavioural history interview</td>
<td>Disturbed diurnal rhythm: evidence of severe disruption of diurnal rhythm</td>
<td>NR</td>
</tr>
<tr>
<td><strong>Severe dementia (MMSE 0-9)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55 Wetzels</td>
<td>2010</td>
<td>NPI nursing home version</td>
<td>Difficulty sleeping, up at night, wander at night</td>
<td>6</td>
</tr>
<tr>
<td><strong>Dementia severity not reported</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34 Jost</td>
<td>1996</td>
<td>Medical record review</td>
<td>Diurnal change</td>
<td>NR</td>
</tr>
</tbody>
</table>

Reference numbers refer to the Online Reference List

Papers from the same study groups:
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece)
2 Maasbed study
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol)
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich)
5 Hope et al. (Oxford)

Apa=apathy
Dep=depression
Anx=anxiety
Irr=irritability/aggression
Agi=agitation
Hal=hallucination
Per=persecution
Mis=misidentification
Sle=sleep problems
Wan=wandering
Ela=elation
Fig. DS2  Persistence of BPSD reported in included studies

Apathy

Depression

Anxiety
Fig. DS2 continued

**Irritability**

<table>
<thead>
<tr>
<th>Period</th>
<th>Persistence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months</td>
<td>5%</td>
</tr>
<tr>
<td>6 months</td>
<td>10%</td>
</tr>
<tr>
<td>12 months</td>
<td>20%</td>
</tr>
<tr>
<td>18 months</td>
<td>30%</td>
</tr>
<tr>
<td>24 months</td>
<td>40%</td>
</tr>
<tr>
<td>Until death</td>
<td>50%</td>
</tr>
</tbody>
</table>

Devenand et al. 5 yrs (Markov)
Aalten et al. 24 (2 visits) - “irritability”
Aalten et al. 24 (2 visits) - “agitation”
Eustace et al. 24 (Markov)
Aalten et al. 24 (3 visits) - “irritability”
Aalten et al. 24 (3 visits) - “agitation”
Devenand et al. 5 yrs (4 visits)
Aalten et al. 24 (4 visits) - “irritability”
Aalten et al. 24 (4 visits) - “agitation”
Aalten et al. 24 (5 visits) - “irritability”
Aalten et al. 24 (5 visits) - “agitation”
Haupt et al. 24 (3 visits)

**Agitation**

<table>
<thead>
<tr>
<th>Period</th>
<th>Persistence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months</td>
<td>5%</td>
</tr>
<tr>
<td>6 months</td>
<td>10%</td>
</tr>
<tr>
<td>12 months</td>
<td>20%</td>
</tr>
<tr>
<td>18 months</td>
<td>30%</td>
</tr>
<tr>
<td>24 months</td>
<td>40%</td>
</tr>
<tr>
<td>Until death</td>
<td>50%</td>
</tr>
</tbody>
</table>

Devenand et al. 5 yrs (Markov)
Aalten et al. 24 (2 visits)
Eustace et al. 24 (Markov)
Aalten et al. 24 (3 visits)
Volcker et al. 15 (4 visits)
Devenand et al. 5 yrs (4 visits)
Aalten et al. 24 (4 visits)
Haupt et al. 24 (3 visits)
Aalten et al. 24 (5 visits)

**Hallucination**

<table>
<thead>
<tr>
<th>Period</th>
<th>Persistence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months</td>
<td>5%</td>
</tr>
<tr>
<td>6 months</td>
<td>10%</td>
</tr>
<tr>
<td>12 months</td>
<td>20%</td>
</tr>
<tr>
<td>18 months</td>
<td>30%</td>
</tr>
<tr>
<td>24 months</td>
<td>40%</td>
</tr>
<tr>
<td>Until death</td>
<td>50%</td>
</tr>
</tbody>
</table>

Devenand et al. 5 yrs (Markov)
Aalten et al. 24 (2 visits)
Eustace et al. 24 (Markov)
Aalten et al. 24 (3 visits)
Devenand et al. 5 yrs (4 visits)
Aalten et al. 24 (4 visits)
Haupt et al. 24 (3 visits)
Aalten et al. 24 (5 visits)
Hope et al. max 9 yrs (visits every 4 months)
The figures show the percentage of participants in which the symptom persisted over the period indicated on the y-axis, and the 95% confidence interval. For each figure, a legend shows the author name, the duration of the total follow-up in months and the number of visits.
### Table DS3  Persistence and remission of symptoms in those with symptoms at baseline

#### Affective symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Depression / Anxiety / Apathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Per measurement (%)</td>
<td>Over total follow-up (%)</td>
</tr>
<tr>
<td>Mild dementia (MMSE 21-26)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Eustace</td>
<td>2002</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>Transition probabilities (Markov model)</td>
</tr>
<tr>
<td>16</td>
<td>Clare</td>
<td>2012</td>
<td>DC</td>
<td>20</td>
<td>3</td>
<td>8-12</td>
<td>Random effects regression analysis.</td>
</tr>
<tr>
<td>Moderate dementia (MMSE 15-20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Levy</td>
<td>1996</td>
<td>NR</td>
<td>12</td>
<td>5</td>
<td>3</td>
<td>No model; Present at all five visits when present at baseline.</td>
</tr>
<tr>
<td>8</td>
<td>Berger</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>3-6</td>
<td>Total: each measurement time over 2 year period. Fluctuation: Present at 50% or more / less than 50% of measurement time over 2 yr. period.</td>
</tr>
<tr>
<td>20</td>
<td>Devanand</td>
<td>1997</td>
<td>DC</td>
<td>5 yrs. (mean 3 yrs.)</td>
<td>7</td>
<td>6</td>
<td>Per obs: Markov model; Total: present at any 4 visits; Fluctuating: present at 1 2 or 3 visits of any 4 visits.</td>
</tr>
<tr>
<td>24</td>
<td>Garre-Olmo</td>
<td>2010</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Linear and quadratic growth mixture models.</td>
</tr>
<tr>
<td>1</td>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Present at any consecutive period of 6, 12, 18, 24 months.</td>
</tr>
<tr>
<td>ID</td>
<td>Author</td>
<td>Year</td>
<td>Setting</td>
<td>Duration</td>
<td>N</td>
<td>Measure</td>
<td>Description</td>
</tr>
<tr>
<td>----</td>
<td>--------</td>
<td>------</td>
<td>---------</td>
<td>----------</td>
<td>---</td>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>2</td>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td></td>
<td>Repeated measure analysis between symptoms and baseline and follow-up, adjusted for MMSE and duration of illness.</td>
</tr>
<tr>
<td>59</td>
<td>Zahodne</td>
<td>2013</td>
<td>DC</td>
<td>5.5 yrs.</td>
<td>6</td>
<td>Latent growth curve modelling.</td>
<td>No significant change - stable over time</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

<table>
<thead>
<tr>
<th>ID</th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Duration</th>
<th>N</th>
<th>Measure</th>
<th>Description</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Fauth</td>
<td>2006</td>
<td>NR</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>Latent growth curve modelling. A linear model of symptom change over time was compared to a model with a quadratic component and the fixed and random growth curve parameters of initial level, linear slope and quadratic slope were estimated. Log BPSD (frequency × duration +10) Covariates: MMSE score, use of neuroleptic medication, use of cholinesterase inhibitor, age, use of in-home respite care, relationship caregiver.</td>
<td>Mood: Quadratic model. Significant intra-individual variability in rate of change</td>
</tr>
<tr>
<td>6</td>
<td>Ballard</td>
<td>1996</td>
<td>CLIN/DC</td>
<td>12</td>
<td>12</td>
<td>1</td>
<td>Percentage with minor dep at baseline that had 3 or more months dep; 6 or more months.</td>
<td>Dep: 28.6; 23.8</td>
</tr>
<tr>
<td>30</td>
<td>Hope</td>
<td>1999</td>
<td>CLIN</td>
<td>9 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Percentage with a single episode that persists until the last interview before death; Fluctuating: A single episode ending before death, more than one discrete episode, the behaviour may or may not persist until death.</td>
<td>Dep: 37 Anx: 32 Dep: 47; 16 Anx: 57; 11</td>
</tr>
<tr>
<td>Page</td>
<td>Author</td>
<td>Year</td>
<td>Region</td>
<td>Max:</td>
<td>Max:</td>
<td>Dep:</td>
<td>Dep:</td>
<td>Dep:</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>------</td>
<td>--------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>47</td>
<td>Neundorfer</td>
<td>2001</td>
<td>DC</td>
<td>max: 5yrs</td>
<td>max: 10</td>
<td>12</td>
<td>Hierarchical modelling or multilevel analysis.</td>
<td>Changes over time within patients and differences between patients.</td>
</tr>
<tr>
<td>27</td>
<td>Haupt$^4$</td>
<td>2000</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>% of those with symptoms at baseline with symptoms after 1 and 2 years; Fluctuating: % with symptoms after 1 or 2 yrs.; % symptoms absent.</td>
<td>58.8 Anx: 33.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Severe dementia (MMSE 0-9)</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4 months.</td>
<td>70.0, 37.5, 12.4, 0.0 Anx: 39.8, 42.9, 24.8, 31.4 Ape: 54.8, 36.0, 51.9, 39.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Normal cognitive function (MMSE 27+, no dementia)</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Kohler</td>
<td>2010</td>
<td>POP</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>Stability defined as a score within the upper quartile group on 2 consecutive assessments: highly depressed at baseline only (fluctuating), highly depressed at follow-up only (fluctuating) and persistently highly depressed (total).</td>
<td>12</td>
</tr>
<tr>
<td>41</td>
<td>Mackin</td>
<td>2011</td>
<td>VOL</td>
<td>3 yrs.</td>
<td>4</td>
<td>12</td>
<td>Proportion of individuals who remained stable, declined, improved, or fluctuated over 3 years was calculated and compared between groups using Fisher’s exact test.</td>
<td>49 stable</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparing cognitive groups</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Li</td>
<td>2001</td>
<td>DC + VOL</td>
<td>93.6</td>
<td>NR</td>
<td>3-12</td>
<td>Persistent: All HDRS scores during follow-up &gt;7 Improved (fluctuating): All HDRS scores during follow-up &lt;7 Fluctuating: HDRS scores at follow-up &gt;7 or &lt;7.</td>
<td>26.6; 66.7; MCI 60.0</td>
</tr>
</tbody>
</table>
### Psychotic symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39 Levy</td>
<td>1996</td>
<td>NR</td>
<td>12</td>
<td>5</td>
<td>3</td>
<td>No model; Present at all five visits when present at baseline.</td>
<td>Psy: 68-82</td>
</tr>
<tr>
<td>8 Berger</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>3-6</td>
<td>Total: each measurement time over 2 year period; Fluctuation: Present at 50% or more / less than 50% of measurement time over 2 year period.</td>
<td>Psy: 24</td>
</tr>
<tr>
<td>20 Devanand*</td>
<td>1997</td>
<td>DC</td>
<td>5 yrs. (mean 3yrs)</td>
<td>7</td>
<td>6</td>
<td>Per obs: Markov model; Total: present at any 4 visits; Fluctuating: present at 1; 2; 3 of any 4 visits.</td>
<td>Del: 59 (includes mis) Hal: 52</td>
</tr>
<tr>
<td>24 Garre-Olmo</td>
<td>2010</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Linear and quadratic growth mixture models.</td>
<td>Factor score: Moderate and stable: 6.9%, Fluctuating: 6.9%, Low and stable 86.2%</td>
</tr>
<tr>
<td>1 Aalten†</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Present at any consecutive period of 6, 12, 18, 24 months.</td>
<td>Del: 11.1; 3; 4; 4 Hal: 5.1; 1; 1; 2</td>
</tr>
<tr>
<td>Study</td>
<td>Authors</td>
<td>Year</td>
<td>Setting</td>
<td>Follow-up</td>
<td>Duration</td>
<td>NPI</td>
<td>Associated Features</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
<td>-----------</td>
<td>----------</td>
<td>-----</td>
<td>---------------------</td>
</tr>
<tr>
<td>2</td>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Repeated measure analysis between symptoms and baseline and follow-up, adjusted for MMSE and duration of illness.</td>
</tr>
<tr>
<td>49</td>
<td>Rosen</td>
<td>1991</td>
<td>DC</td>
<td>6 yrs.</td>
<td>7</td>
<td>1yr</td>
<td>Percentage remission of those with at least one follow-up visit after onset symptom (n=6).</td>
</tr>
<tr>
<td>19</td>
<td>Deudon</td>
<td>2009</td>
<td>CH</td>
<td>3</td>
<td>3</td>
<td>1 or 2</td>
<td>Mixed linear model with random effect. Covariates: age.</td>
</tr>
<tr>
<td>5</td>
<td>Ballard</td>
<td>1997</td>
<td>CLIN/DC</td>
<td>12</td>
<td>12</td>
<td>1</td>
<td>Resolution of symptoms in those followed-up for a yr.</td>
</tr>
<tr>
<td>44</td>
<td>McShane</td>
<td>1995</td>
<td>CLIN</td>
<td>5 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Proportion of interviews were hallucinations were present.</td>
</tr>
<tr>
<td>30</td>
<td>Hope</td>
<td>1999</td>
<td>CLIN</td>
<td>9 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Percentage with a single episode that persists until the last interview before death; Fluctuating: A single episode ending before death; More than one discrete episode, the behaviour may or may not persist until death.</td>
</tr>
<tr>
<td>27</td>
<td>Haupt</td>
<td>2000</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>% of those with symptoms at baseline with symptoms after 1 and 2 years; Fluctuating: % with symptoms after 1 or 2 years; % symptoms absent.</td>
</tr>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4.</td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Authors</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Duration</th>
<th>NPI</th>
<th>Associated Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Deudon</td>
<td>2009</td>
<td>CH</td>
<td>3</td>
<td>3</td>
<td>1 or 2</td>
<td>Mixed linear model with random effect. Covariates: age.</td>
</tr>
<tr>
<td>5</td>
<td>Ballard</td>
<td>1997</td>
<td>CLIN/DC</td>
<td>12</td>
<td>12</td>
<td>1</td>
<td>Resolution of symptoms in those followed-up for a yr.</td>
</tr>
<tr>
<td>44</td>
<td>McShane</td>
<td>1995</td>
<td>CLIN</td>
<td>5 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Proportion of interviews were hallucinations were present.</td>
</tr>
<tr>
<td>30</td>
<td>Hope</td>
<td>1999</td>
<td>CLIN</td>
<td>9 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Percentage with a single episode that persists until the last interview before death; Fluctuating: A single episode ending before death; More than one discrete episode, the behaviour may or may not persist until death.</td>
</tr>
<tr>
<td>27</td>
<td>Haupt</td>
<td>2000</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>% of those with symptoms at baseline with symptoms after 1 and 2 years; Fluctuating: % with symptoms after 1 or 2 years; % symptoms absent.</td>
</tr>
</tbody>
</table>

**Severe dementia (MMSE 0-9)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Authors</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Duration</th>
<th>NPI</th>
<th>Associated Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4.</td>
</tr>
</tbody>
</table>

Psy: F=28.3, p<0.001. Also associated with baseline NPI total and hyperactivity, not mood/apathy.

Psy: 33

Psy: 53 Del: 73 Hal: 61 Mis: 65

Del: 23 Hal: 42 Del: 68; 9 Hal: 42; 17

Del: 0 Hal: 0 Del: 42.9; 57.1 Hal: 72.7; 27.3
## Hyperactivity symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Irritability / Agitation / Wandering</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Eustace</td>
<td>2002</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12 Transition probabilities (Markov model).</td>
<td>Irr: 70</td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Levy</td>
<td>1996</td>
<td>NR</td>
<td>12</td>
<td>5</td>
<td>3 No model; Present at all five visits when present at baseline.</td>
<td>Agi/Wan: 65-67</td>
</tr>
<tr>
<td>8</td>
<td>Berger</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>3-6 Total: each measurement time over 2 year period Fluctuation: Present at 50% or more / less than 50% of measurement time over 2 year period.</td>
<td>Agi/Wan: 65-67</td>
</tr>
<tr>
<td>20</td>
<td>Devanand</td>
<td>1997</td>
<td>DC</td>
<td>5 yrs.</td>
<td>7</td>
<td>6 Per obs: Markov model; Total: present at any 4 visits; Fluctuating: present at 1; 2; 3 of any 4 visits.</td>
<td>Agi/Wan: 74 Irr: 2.8</td>
</tr>
<tr>
<td>24</td>
<td>Garre-Olmo</td>
<td>2010</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6 Linear and quadratic growth mixture models.</td>
<td>Factor score: Low and smooth increasing: 66.6%, High and increasing: 4.3%, Moderate and stable: 17.5%, Low and sharp increasing: 11.6%</td>
</tr>
<tr>
<td></td>
<td>Author(s)</td>
<td>Year</td>
<td>Country</td>
<td>N</td>
<td>Follow-up (months)</td>
<td>Symptom Measurement</td>
<td>Methodology</td>
</tr>
<tr>
<td>---</td>
<td>-----------</td>
<td>------</td>
<td>---------</td>
<td>----</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>1</td>
<td>Aalten*</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>present</td>
</tr>
<tr>
<td>2</td>
<td>Aalten*</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Repeated</td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

<p>| 19 | Deudon   | 2009 | CH      | 3  | 3                 | 1 or 2         | Mixed linear model with random effect. Covariates: age. | Global CMAI: beta=0.02 (0.797) Physically non-aggressive behaviour: beta=-0.003 (0.368), verbally non-aggressive behaviour: beta=0.001 (0.832) NPI hyperactivity factor: beta=0.35 (0.091) Physically aggressive behaviour: beta=0.004 (0.11), verbally aggressive behaviour: beta=-0.001 (0.776). Observation scale: beta=-0.16 (0.17) |</p>
<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Journal</th>
<th>Study Type</th>
<th>Duration</th>
<th>Level</th>
<th>Slope</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>Fauth</td>
<td>NR</td>
<td>Latent growth curve modelling. A linear model of symptom change over time was compared to a model with a quadratic component and the fixed and random growth curve parameters of initial level, linear slope and quadratic slope were estimated. Log BPSD (frequency × duration +10) Covariates: MMSE score, use of neuroleptic medication, use of cholinesterase inhibitor, age, use of in-home respite care, relationship caregiver.</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>Disruptive problems: Quadratic model. Disruptive behaviour: Significant intra-individual variability in rate of change Restlessness: linear model. Significant variability of people’s baseline scores.</td>
</tr>
<tr>
<td>1999</td>
<td>Keene</td>
<td>CLIN</td>
<td>Persistence: Percentage with a single episode that persists until the last interview before death; Fluctuating: A single episode ending before death; More than one discrete episode, the behaviour may or may not persist until death.</td>
<td>10 yrs.</td>
<td>30</td>
<td>4</td>
<td>Irr: verbal aggression: 54; aggressive resistance 60; physical aggression 51; physical threats 29; refusal to speak 17; destructive behaviour 28; general irritability 14; carer avoids aggression 44 (Same population as Hope et al. ref 43)</td>
</tr>
<tr>
<td>30</td>
<td>Hope(^a)</td>
<td>1999</td>
<td>CLIN</td>
<td>9 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Percentage with a single episode that persists until the last interview before death; Fluctuating: A single episode ending before death; More than one discrete episode, the behaviour may or may not persist until death.</td>
</tr>
<tr>
<td>27</td>
<td>Haupt(^a)</td>
<td>2000</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>% of those with symptoms at baseline with symptoms after 1 and 2 years; Fluctuating: % with symptoms after 1 or 2 years; % symptoms absent.</td>
</tr>
</tbody>
</table>

**Severe dementia (MMSE 0-9)**

<p>| 55 | Wetzes | 2010 | CH | 24 | 5 | 6 | No model. For each observation 0-1, 1-2, 2-3, 3-4. | Irr (&quot;agitation&quot;): 51.4, 51.9, 37.6, 56.1 Irr (&quot;irritability&quot;): 54.1, 55.2, 62.4, 52.9 Agi/Wan: 63.0, 58.1, 41.9, 59.0 | Irr (&quot;agitation&quot;): 21.2, 1.9 |</p>
<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Country</th>
<th>Study Type</th>
<th>Sample Size</th>
<th>Follow-up</th>
<th>Methodology</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Burgio</td>
<td>CH</td>
<td>Multilevel</td>
<td>18</td>
<td>4</td>
<td>6</td>
<td>Multilevel analysis. Restricted maximum likelihood estimation method with a specification of the unstructured covariance. Analysed linear and curvilinear time effects.</td>
</tr>
<tr>
<td>2012</td>
<td>de Rooij</td>
<td>CH</td>
<td>Changes</td>
<td>12</td>
<td>3</td>
<td>6</td>
<td>Staff: Agitation changed little over the 18 month period; Obs: Both linear and quadratic effect were statistically significant (p&lt;0.05) indicating that the trajectory of agitation had a decreasing trend linearly but the rate of decrease lessened over time.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>King-Kallimanis</td>
<td>CH</td>
<td>Total</td>
<td>4 yrs. (mean 390/297 days)</td>
<td>3</td>
<td></td>
<td>Total: Wan at admission and for the duration of the study Fluctuating: Wan at admission and one change to a non-wan; Wan at admission and changed to wan and back to wan; Wan at admission and fluctuated multiple times. (% of all wan at baseline).</td>
</tr>
<tr>
<td>2012</td>
<td>Volicer</td>
<td>CH</td>
<td>Four groups</td>
<td>15</td>
<td>4</td>
<td>3</td>
<td>Agi: increased 19.6, decreased 16.7, stable 46.2, no agi 17.3</td>
</tr>
</tbody>
</table>

**Dementia severity not reported**

<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Country</th>
<th>Study Type</th>
<th>Sample Size</th>
<th>Follow-up</th>
<th>Methodology</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>King-Kallimanis</td>
<td>CH</td>
<td>Total</td>
<td>4 yrs. (mean 390/297 days)</td>
<td>3</td>
<td></td>
<td>Total: Wan at admission and for the duration of the study Fluctuating: Wan at admission and one change to a non-wan; Wan at admission and changed to wan and back to wan; Wan at admission and fluctuated multiple times. (% of all wan at baseline).</td>
</tr>
<tr>
<td>2012</td>
<td>Volicer</td>
<td>CH</td>
<td>Four groups</td>
<td>15</td>
<td>4</td>
<td>3</td>
<td>Agi: increased 19.6, decreased 16.7, stable 46.2, no agi 17.3</td>
</tr>
</tbody>
</table>
Repeated measures multivariate analyses of variances (MANOVA) CMAI syndrome scores: mean of behaviours comprising each type of agitation.

<table>
<thead>
<tr>
<th>Elation</th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Elation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Verbally non-aggressive behaviour increased F=270, p=0.03; Physical non-aggressive behaviour NS Verbally aggressive behaviour increased over time F=3.83, p&lt;0.01, Physically aggressive behaviour increased over time F=4.43, p&lt;0.01</td>
<td>Per measurement (%)</td>
</tr>
<tr>
<td>Elation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate dementia (MMSE 15-20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Aalten*</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td></td>
<td>Present at any consecutive period of 6, 12, 18, 24 months.</td>
<td>2, 0, 0, 0</td>
</tr>
<tr>
<td>Severe dementia (MMSE 0-9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55 Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4.</td>
<td>39.5, 17.6, 33.3, 20.9</td>
<td></td>
</tr>
</tbody>
</table>
### Sleep problems

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Sleep problems</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Per measurement (%)</td>
<td>Over total follow-up (%)</td>
</tr>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 Eustace</td>
<td>2002</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>Transition probabilities (Markov model).</td>
<td>68</td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Berger</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>3-6</td>
<td>Total: each measurement time over 2 year period; Fluctuation: Present at 50% or more / less than 50% of measurement time over 2 year period.</td>
<td>9</td>
</tr>
<tr>
<td>23 Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Present at any consecutive period of 6, 12, 18, 24 months.</td>
<td>10.1; 1; 1</td>
</tr>
<tr>
<td><strong>Moderately severe dementia (MMSE 10-14)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23 Fauth</td>
<td>2006</td>
<td>NR</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>Latent growth curve modelling. A linear model of symptom change over time was compared to a model with a quadratic component and the fixed and random growth curve parameters of initial level, linear slope and quadratic slope were estimated. Log BPSD (frequency × duration +10) Covariates: MMSE score, use of neuroleptic medication, use of cholinesterase inhibitor, age, use of in-home respite care, relationship caregiver.</td>
<td>Linear model. Significant variability of people's baseline scores. Intra-individual variability NS</td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Setting</td>
<td>Months follow-up</td>
<td>n BPSD measures</td>
<td>Time between measures (months)</td>
<td>Details</td>
<td>Total score</td>
</tr>
<tr>
<td>----------</td>
<td>--------</td>
<td>---------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Severe dementia (MMSE 0-9)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4. Slie: 56.7, 50.0, 0.0, 20.9</td>
<td></td>
</tr>
</tbody>
</table>

**Total BPSD score**

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Total score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clare</td>
<td>2012</td>
<td>DC</td>
<td>20</td>
<td>3</td>
<td>8-12</td>
<td>Random effects regression analysis. Significant increase over time (lope 0.17, p&lt;0.001), no significant change in severity</td>
<td></td>
</tr>
<tr>
<td>Tschanz</td>
<td>2011</td>
<td>PB</td>
<td>Mean 3.8 yrs., max 12.9 yrs.</td>
<td>NR</td>
<td>NR</td>
<td>Linear effects models, annual rate of change in NPI total. Increase of total NPI score over time: intercept: 2.5, time 3.1 (p=0.002)</td>
<td></td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aalten†</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Repeated measure analysis between symptoms and baseline and follow-up, adjusted for MMSE and duration of illness. NPI: F=16.5, p&lt;0.001 Also associated with baseline mood/apathy, hyperactivity and psy</td>
<td></td>
</tr>
</tbody>
</table>
Latent growth curve modelling. A linear model of symptom change over time was compared to a model with a quadratic component and the fixed and random growth curve parameters of initial level, linear slope and quadratic slope were estimated. Log BPSD (frequency × duration +10) Covariates: MMSE score, use of neuroleptic medication, use of cholinesterase inhibitor, age, use of in-home respite care, relationship caregiver.

No fixed or linear quadratic parameters were significant - on average no significant change over time for any domain, BPSD stable over 3 months

Reference numbers refer to the Online Reference List

Papers from the same study groups:
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece)
2 Maxsbed study
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol)
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich)
5 Hope et al. (Oxford)

Settings
DC=Dementia or memory clinic
POP=Population-based
CH=Care home
CLIN=Referred by clinicians
VOL=Volunteers
NR=Not reported

BPSD= behavioural and psychological symptoms of dementia
Apa=apathy
Dep=depression
Anx=anxiety
Irr=irritability/aggression
Agi=agitation
Hal=hallucination
Per=persecution
Mis=misidentification
Sle=sleep problems
Wan=wandering
El=elation

MMSE=mini mental state examination; mMmMSE=modified mini mental state examination; SEM=standard error of the mean
Table DS4  Incidence and absence of symptoms in those without symptoms at baseline

Affective symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Depression / Anxiety / Apathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Per measurement (%)</td>
</tr>
</tbody>
</table>

**Mild dementia (MMSE 21-26)**


**Moderate dementia (MMSE 15-20)**

<p>| 39     | Levy   | 1996    | NR               | 12             | 5                             | Rate of new appearance of a symptom during the observation period in patients who had not reported the symptom at study onset. | Dep: 35 |
| 8      | Berger | 2005    | DC               | 24             | 5                             | Absent at each measurement time over the 2 yr. period. | Dep: 24 Anx: 31 |
| 50     | Scarmeas$^{1a}$ | 2002 | NR | 9.3 yrs. | NR | 6 | Manifesting incident symptoms at any follow-up visit. Calculated from manifesting symptom at follow-up and no symptom at first visit. | Dep: 73.5 |
| 20     | Devanand$^{1a}$ | 1997 | DC | 5 yrs. (mean 3 yrs.) | 7 | 6 | Markov model. Absent: Of participants that completed 4 consecutive periods of 6 months: present at none of the 4 visits. | Dep: 14 |
| 1      | Aalten$^{2a}$ | 2005 | DC | 24 | 5 | 6 | Cumulative incidence: the proportion of patients who were symptom free at baseline but developed the specific symptom at next assessments. | Dep: 33.4 Anx: 27.5 Apa: 63.9 |</p>
<table>
<thead>
<tr>
<th>25</th>
<th>Gillette-Guyonnet</th>
<th>2011</th>
<th>DC</th>
<th>max 48</th>
<th>mean 5.1</th>
<th>6</th>
<th>Incidence of NPI 4 or higher per 100 person years and % events during 4 year follow-up in those without the symptom at baseline (between brackets).</th>
<th>Dep: 16.5 (29.5) Anx: 19.6 (33.9) Apa: 41.7 (55.7)</th>
</tr>
</thead>
</table>

**Moderately severe dementia (MMSE 10-14)**

<table>
<thead>
<tr>
<th>6</th>
<th>Ballard⁴</th>
<th>1996</th>
<th>CLIN</th>
<th>12</th>
<th>12</th>
<th>1</th>
<th>Without major or minor depression at baseline interview</th>
<th>Dep: 29.8 minor; 10.6 major</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>27</th>
<th>Haupt⁴</th>
<th>2000</th>
<th>DC</th>
<th>24</th>
<th>3</th>
<th>12</th>
<th>Absent at baseline and present after 1 or 2 years / 1 and 2 years (% without symptoms at baseline). Absent: absent at baseline and after 1 or 2 years (% without symptom at baseline).</th>
<th>Dep: 26.9; 26.9 Anx: 38.5; 7.7</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>14</th>
<th>Chang</th>
<th>2004</th>
<th>DC</th>
<th>mean: 51.9</th>
<th>NR</th>
<th>NR</th>
<th>Symptoms developed during follow-up period, those with symptoms at baseline excluded.</th>
<th>Dep: 12.5</th>
</tr>
</thead>
</table>

**Severe dementia (MMSE 0-9)**

<table>
<thead>
<tr>
<th>55</th>
<th>Wetzels</th>
<th>2010</th>
<th>CH</th>
<th>24</th>
<th>5</th>
<th>6</th>
<th>No model. For each observation 0-1, 1-2, 2-3, 3-4.</th>
<th>Dep: 8.4, 9.8, 3.0, 3.4 Anx: 6.2, 9.7, 11.9, 8.5 Apa: 13.7, 17.4, 27.2, 18.8</th>
</tr>
</thead>
</table>

**Normal cognitive function (MMSE 27+, no dementia)**

<table>
<thead>
<tr>
<th>37</th>
<th>Kohler</th>
<th>2010</th>
<th>POP</th>
<th>6</th>
<th>3</th>
<th>3</th>
<th>Those who had symptoms at follow-up visits only Absent: never highly depressed.</th>
<th>Dep: 25</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>No model. For each observation 0-1, 1-2, 2-3, 3-4.</th>
<th>Dep: 55</th>
</tr>
</thead>
</table>
### Comparing cognitive groups

<table>
<thead>
<tr>
<th></th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Del: out of 100 person years</th>
<th>MCI</th>
<th>VAD</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Li</td>
<td>2001</td>
<td>DC + VOL</td>
<td>93.6</td>
<td>NR</td>
<td>3-12</td>
<td>Annual incidences of new-onset depressive symptoms among non-depressed subjects at baseline. No model. Calculated by dividing cumulative numbers of subjects showing new onset depressive symptoms (HDRS&gt;7) by mean interval of follow-up years.</td>
<td>Dep: AD - 15 per 100 person years (8/26) MCI: 11.7 (5/13) VAD: 26.8 (13/23)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Dementia severity not reported

<table>
<thead>
<tr>
<th></th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Del: out of 100 person years</th>
<th>MCI</th>
<th>VAD</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Jost</td>
<td>1996</td>
<td>DC</td>
<td>Retropective</td>
<td>Retropective</td>
<td>Documentation of onset of symptoms in medical records.</td>
<td>Dep: 72</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Psychotic symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Per measurement (%) Over total follow-up (%) Absent (%)</td>
</tr>
</tbody>
</table>

#### Mild dementia (MMSE 21-26)

<table>
<thead>
<tr>
<th></th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Delusion / Hallucination / Misidentification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>Author</td>
<td>Year</td>
<td>Classification</td>
<td>Follow-up</td>
<td>Observation Period</td>
<td>Methodology</td>
<td>Calculation</td>
<td>Rate of New Appearance of a Symptom</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>------</td>
<td>----------------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------</td>
<td>------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>39</td>
<td>Levy</td>
<td>1996</td>
<td>NR 12</td>
<td>5</td>
<td>3</td>
<td>Rate of new appearance of a symptom during the observation period in patients who had not reported the symptom at study onset.</td>
<td>Del: 25</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Berger</td>
<td>2005</td>
<td>DC 24</td>
<td>5</td>
<td>3-6</td>
<td>Absent at each measurement time over the 2 year period.</td>
<td>Psy: 29</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Scarmeas*</td>
<td>2002</td>
<td>NR 9.3 yrs. NR 6</td>
<td>6</td>
<td>Manifesting incident symptoms at any follow-up visit. Calculated from manifesting symptom at follow-up and no symptom at first visit.</td>
<td>Del: 84.5 Hal: 45.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Devanand*</td>
<td>1997</td>
<td>DC 5 yrs. (mean 3 yrs.) 7</td>
<td>6</td>
<td>Markov model. Absent: Of participants that completed 4 consecutive periods of 6 months: present at none of the 4 visits.</td>
<td>Del: 17 Hal: 9</td>
<td>Del: 30.6 Hal: 60</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Aalten†</td>
<td>2005</td>
<td>DC 24</td>
<td>5</td>
<td>6</td>
<td>Cumulative incidence: the proportion of patients who were symptom free at baseline but developed the specific symptom at next assessments.</td>
<td>Del: 34 Hal: 20.5</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Gillette-Guyonnet</td>
<td>2011</td>
<td>DC max 48 mean 5.1</td>
<td>6</td>
<td>Incidence of NPI 4 or higher per 100 person years and % events during 4 year follow-up in those without the symptom at baseline (between brackets).</td>
<td>Del: 8.2 (16.5) Hal: 4.4 (9.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Rosen</td>
<td>1991</td>
<td>DC 6 yrs. 7</td>
<td>1 yr.</td>
<td>Emerging of psychosis by MMSE score.</td>
<td></td>
<td>82.4 (n=14 of total n=32 of which n=15 with symptoms during course)</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Author</td>
<td>Year</td>
<td>Setting</td>
<td>Follow-up</td>
<td>Derivation of Symptom</td>
<td>Incidence Rates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>------</td>
<td>---------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Paulsen</td>
<td>2000</td>
<td>DC</td>
<td>4 yrs.</td>
<td>5 1 yr.</td>
<td>The cumulative incidence for hallucinations or delusions in patients with a clinical diagnosis of probable AD</td>
<td>20.1% at 1 year, 36.1% at 2 years, 49.5% at 3 years, and 51.3% at 4 years</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Wilkosz</td>
<td>2006</td>
<td>DC</td>
<td>mean: 25.8</td>
<td>NR 1 yr.</td>
<td>Only numbers and incidence rate given, I calculated percentages from this using n=288.</td>
<td>Psy: 28.5 Del: 8.7 Mis: 16.0</td>
<td></td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Derivation of Symptom</th>
<th>Incidence Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Ballard</td>
<td>1997</td>
<td>DC</td>
<td>12 12 1</td>
<td>Percentage without symptoms at baseline that developed symptoms during follow-up.</td>
<td>Psy: 47 Del: 30 Hal: 20 Mis: 17</td>
</tr>
<tr>
<td>27</td>
<td>Haupt</td>
<td>2000</td>
<td>DC</td>
<td>24 3 12</td>
<td>Absent at baseline and present after 1 or 2 yrs. / 1 and 2 yrs. (% without symptoms at baseline). Absent: absent at baseline and after 1 or 2 years (% without symptom at baseline).</td>
<td>Del: 29.7; 0 Hal: 18.8; 2.1 Del: 7 Hal: 79.2</td>
</tr>
<tr>
<td>14</td>
<td>Chang</td>
<td>2004</td>
<td>DC</td>
<td>mean: 51.9</td>
<td>NR NR</td>
<td>Symptoms developed during follow-up period, those with symptoms at baseline excluded.</td>
</tr>
</tbody>
</table>

**Severe dementia (MMSE 0-9)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Derivation of Symptom</th>
<th>Incidence Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24 5 6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4.</td>
<td>Del: 2.9, 5.4, 5.5, 4.3 Hal: 1.8, 2.7, 0.0, 5.1</td>
</tr>
</tbody>
</table>

**Dementia severity not reported**

<table>
<thead>
<tr>
<th>Study</th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Derivation of Symptom</th>
<th>Incidence Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Chen</td>
<td>1991</td>
<td>DC</td>
<td>5 yrs.</td>
<td>2 or more 6</td>
<td>Incidence during follow-up period.</td>
</tr>
<tr>
<td>34</td>
<td>Jost</td>
<td>1996</td>
<td>DC</td>
<td>Retro-reflective using medical records</td>
<td>Retro-reflective Retro-reflective</td>
<td>Documentation of onset of symptoms in medical records.</td>
</tr>
<tr>
<td>13</td>
<td>Caligiuri</td>
<td>2003</td>
<td>DC? NR</td>
<td>24 3 1 yrs.</td>
<td>Incidence rate over 2 yrs. for new onset psychosis (those with symptoms at baseline excluded).</td>
<td>Psy: 32.5</td>
</tr>
</tbody>
</table>
### Hyperactivity symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Irritability / Agitation / Wandering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild dementia (MMSE 21-26)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Eustace</td>
<td>2002</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12 Markov model. Transition probability for onset over 2 yr. period.</td>
<td>Irr: 38</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate dementia (MMSE 15-20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Levy</td>
<td>1996</td>
<td>NR</td>
<td>12</td>
<td>5</td>
<td>3 Rate of new appearance of a symptom during the observation period in patients who had not reported the symptom at study onset.</td>
<td>Agi/Wan: 39</td>
</tr>
<tr>
<td>8</td>
<td>Berger</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>3-6 Absent at each measurement time over the 2 year period.</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Scarmeas</td>
<td>2002</td>
<td>NR</td>
<td>9.3 yrs.</td>
<td>NR</td>
<td>6 Manifesting incident symptoms at any follow-up visit. Calculated from manifesting symptom at follow-up and no symptom at first visit.</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Devanand</td>
<td>1997</td>
<td>DC</td>
<td>5 yrs. (mean 3 yrs.)</td>
<td>7</td>
<td>6 Markov model. Absent: Of participants that completed 4 consecutive periods of 6 months: symptom present at none of the 4 visits.</td>
<td>Agi/Wan: 31 Irr: 10</td>
</tr>
<tr>
<td></td>
<td>Author(s)</td>
<td>Year</td>
<td>Setting</td>
<td>Follow-up</td>
<td>Cases</td>
<td>Time Interval</td>
<td>Description</td>
</tr>
<tr>
<td>---</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
<td>-----------</td>
<td>-------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Cumulative incidence: the proportion of patients who were symptom free at baseline but developed the specific symptom at next assessments.</td>
</tr>
<tr>
<td>25</td>
<td>Gillette-Guyonnet</td>
<td>2011</td>
<td>DC</td>
<td>max 48</td>
<td>mean 5.1</td>
<td>6</td>
<td>Incidence of NPI 4 or higher per 100 person years and % events during 4 year follow-up in those without the symptom at baseline (between brackets).</td>
</tr>
</tbody>
</table>

**Moderately severe dementia (MMSE 10-14)**

<table>
<thead>
<tr>
<th></th>
<th>Author(s)</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Cases</th>
<th>Time Interval</th>
<th>Description</th>
<th>Incidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>McShane</td>
<td>1998</td>
<td>CLIN</td>
<td>4 yrs.</td>
<td>NR</td>
<td>4</td>
<td>Newly developed behaviours during 3 year period (association with symptoms in first year also reported).</td>
<td>Irr: 31; Agi: 16.7</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Haupt</td>
<td>2000</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>12</td>
<td>Absent at baseline and present after 1 or 2 years / 1 and 2 years (% without symptoms at baseline). Absent: absent at baseline and after 1 or 2 years (% without symptom at baseline).</td>
<td>Agi: 28.6; 71.4 Irr: 31.3; 18.8 Agi: 0 Irr: 50</td>
<td></td>
</tr>
</tbody>
</table>

**Severe dementia (MMSE 0-9)**

<table>
<thead>
<tr>
<th></th>
<th>Author(s)</th>
<th>Year</th>
<th>Setting</th>
<th>Follow-up</th>
<th>Cases</th>
<th>Time Interval</th>
<th>Description</th>
<th>Incidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4.</td>
<td>Irr (&quot;agitation&quot;): 9.5, 20.6, 15.3, 23.1 Irr (&quot;agitation&quot;): 17.2, 18.2, 16.5, 23.1 Agi/Wan: 15.6, 15.1, 10.5, 18.8</td>
<td></td>
</tr>
</tbody>
</table>
### Dementia severity not reported

<table>
<thead>
<tr>
<th></th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Elation</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>King-Kallimanis</td>
<td>2010</td>
<td>CH</td>
<td>4 yrs. (mean 390/297 days)</td>
<td>mean:4</td>
<td>3</td>
<td>Of non-wan at admission, changed to wan and remained wan; Of non-wan at admission, changed to wan and back to non-wan; Of non-wan at admission, changed to wan and fluctuated. Absent: Of non-wan at admission, % that remained non wan for the duration of the study or until discharge.</td>
<td>Wan: 3;2; 1</td>
<td>Wan: 94</td>
</tr>
<tr>
<td>46; 38</td>
<td>Morgan; Kunik</td>
<td>2012</td>
<td>DC</td>
<td>24</td>
<td>7</td>
<td>4</td>
<td>Incidence during follow-up period (incidence in first 5 months excluded in Morgan 2012, included in Kunik 2010).</td>
<td>Agg: 38 (Morgan); 41 (Kunik)</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Jost</td>
<td>1996</td>
<td>DC</td>
<td>Retrospective using medical records</td>
<td>Retro-spective</td>
<td>Retro-spective</td>
<td>Documentation of onset of symptoms in medical records.</td>
<td>Irr: 77 Wan: 43</td>
<td></td>
</tr>
</tbody>
</table>

### Elation

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Elation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Per measurement (%)</td>
</tr>
</tbody>
</table>

**Moderate dementia (MMSE 15-20)**

<table>
<thead>
<tr>
<th></th>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Elation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Cumulative incidence: the proportion of patients who were symptom free at baseline but developed the specific symptom at the next assessments.</td>
<td>4.6</td>
</tr>
</tbody>
</table>
### Sleep problems

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Sleep problems</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Severe dementia (MMSE 0-9)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.9 (8.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mild dementia (MMSE 21-26)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Eustace</td>
<td>2002</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>Markov model. Transition probability for onset over 2 year period.</td>
<td>15</td>
</tr>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Berger</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>Absent at each measurement time over the 2 year period.</td>
<td>44</td>
</tr>
<tr>
<td>1</td>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>Cumulative incidence: the proportion of patients who were symptom free at baseline but developed the specific symptom at next assessments.</td>
<td>30.6</td>
</tr>
<tr>
<td>25</td>
<td>Gillette-Guyonnet</td>
<td>2011</td>
<td>DC</td>
<td>max 48</td>
<td>mean 5.1</td>
<td>6</td>
<td>Incidence of NPI 4 or higher per 100 person years and % events during 4 year follow-up in those without the symptom at baseline (between brackets).</td>
</tr>
<tr>
<td><strong>Severe dementia (MMSE 0-9)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Wetzels</td>
<td>2010</td>
<td>CH</td>
<td>24</td>
<td>5</td>
<td>No model. For each observation 0-1, 1-2, 2-3, 3-4.</td>
<td>1.8, 6.3, 4.7, 8.5</td>
</tr>
</tbody>
</table>
### Dementia severity not reported

<table>
<thead>
<tr>
<th>34</th>
<th>Jost</th>
<th>1996</th>
<th>DC</th>
<th>Retrospective using medical records</th>
<th>Retrospective</th>
<th>Documentation of onset of symptoms in medical records</th>
<th>56%</th>
</tr>
</thead>
</table>

Reference numbers refer to the Online Reference List

Papers from the same study groups:

1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA

1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece)

2 Maasbed study

3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol)

4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich)

5 Hope et al. (Oxford)

Settings

DC=Dementia or memory clinic

POP=Population-based

CH=Care home

CLIN=Referred by clinicians

VOL=Volunteers

NR=Not reported

BPSD= behavioural and psychological symptoms of dementia

Apa=apathy

Dep=depression

Anx=anxiety

Irr=irritability/aggression

Agi=agitation

Hal=hallucination

Per=persecution

Mis=misidentification

Sle=sleep problems

Wan=wandering

Ela=elation
Fig. DS3  Incidence of BPS reported in included studies

Apathy

- Aalten et al. 24 (4 visits)
- Gilette-Guyonnete max 4 yrs (mean 5.1 visits)

Depression

- Devenand et al. 5 yrs (Markov)
- Kohler et al. 6 (3 visits)
- Eustace et al. 24 (Markov)
- Levy et al. 12 (5 visits)
- Ballard et al. 12 (13 visits)
- Aalten et al. 24 (4 visits)
- Haupt et al. 24 (3 visits)
- Gilette-Guyonnete max 4 yrs (mean 5.1 visits)
- Chang et al. mean 51.0 (NR)
- Scarmeas et al. max 9.8yrs (visits every 6 months)

Anxiety

- Eustace et al. 24 (Markov)
- Aalten et al. 24 (6 visits)
- Haupt et al. 24 (3 visits)
- Gilette-Guyonnete max 4 yrs (mean 3.1 visits)
Fig. DS3 continued

**Irritability**

- Devenand et al. 5 yrs (Markov)
- Eustace et al. 24 (Markov)
- Kunik et al. 24 (7 visits)
- Aalten et al. 24 (4 visits) - “Irritability”
- Aalten et al. 24 (4 visits) - “agitation”
- Haupt et al. 24 (3 visits)
- Gilette-Guyonnette max 4 yrs (mean 5.1 visits) - “Irritability”
- Gilette-Guyonnette max 4 yrs (mean 5.1 visits) - “agitation”
- McShane et al. max 4 yrs (visits every 4 months)

**Agitation**

- Devenand et al. 5 yrs (Markov)
- Levy et al. 12 (5 visits)
- Aalten et al. 24 (4 visits)
- Haupt et al. 24 (3 visits)
- Gilette-Guyonnette max 4 yrs (mean 5.1 visits)
- McShane et al. max 4 yrs (visits every 4 months)

**Hallucination**

- Devenand et al. 5 yrs (Markov)
- Ballard et al. 12 (13 visits)
- Eustace et al. 24 (Markov)
- Aalten et al. 24 (4 visits)
- Haupt et al. 24 (3 visits)
- Gilette-Guyonnette max 4 yrs (mean 5.1 visits)
- Chang et al. mean 51.9 (NR)
- Scarmeas et al. max 9.3 yrs (visits every 6 months)
Fig. DS3 continued

**Delusions**

- Devenand et al. 5 yrs (Markov)
- Ballard et al. 12 (13 visits)
- Eustace et al. 24 (Markov)
- Levy et al. 12 (5 visits)
- Wilkosz et al. mean 25.8 (visits every 1 year)
- Aalten et al. 24 (4 visits)
- Haupt et al. 24 (3 visits)
- Gilette-Guyonette max 4 yrs (mean 5.1 visits)
- Chang et al. mean 51.9 (NR)
- Scarmeas et al. max 9.3yrs (visits every 6 months)

**Psychosis**

- Ballard et al. 12 (13 visits)
- Paulsen et al. 12 (2 visits)
- Paulsen et al. 24 (3 visits)
- Caliguri et al. 24 (3 visits)
- Wilkosz et al. mean 25.8 (visits every 1 year)
- Paulsen et al. 36 (4 visits)
- Paulsen et al. 48 (5 visits)
- Chen et al. mean 5yrs (visits every 6 months)
- Rosen et al. 6yrs (7 visits)

**Sleep problems**

- Eustace et al. 24 (Markov)
- Aalten et al. 24 (4 visits)
- Gilette-Guyonette max 4 yrs (mean 5.1 visits)
The figures show the percentage of participants in which new symptoms developed during the period indicated on the y-axis, and the 95% confidence interval. For each figure, a legend shows the author name, the duration of the total follow-up in months and the number of visits.
Table DS5  Association BPSD and cognitive function

### Affective symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Covariates</th>
<th>Score</th>
<th>Depression / Anxiety / Apathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate dementia (MMSE 15-20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 Holtzer</td>
<td>2005</td>
<td>DC</td>
<td>14yrs</td>
<td>28</td>
<td>6</td>
<td>Time-dependent Cox analysis to evaluate if cognitive status predicted the first episode of dep during follow-up. General estimating equation with cognitive status, functional activity and disease duration as predictors, taking into account the multiple visits per patient as well as the likelihood that an individual's characteristics correlate with each other over time. Dichotomous depression outcome, also results for categorical and continuous outcomes in paper.</td>
<td>Time, age, sex, education, cohort, antidepressant medication, Charlson comorbidity index.</td>
<td>1 Depression dichotomous exclusive of physical symptoms, 2 frequency of depression exclusive of physical symptoms (5 level scale), 3 total depression scores inclusive of physical symptoms.</td>
<td>Dep: Time dependent Cox analysis: mMMSE NS. GEE analysis with dichotomous outcome 1: mMMSE: 0.003 (0.000-0.006) (p=0.03), Time: -0.0022 (-0.037-0.007) (p=0.004), BDRS 0.002 (0.001-0.002) (p&lt;0.001); mMMSE NS using other 2 depression outcomes.</td>
</tr>
<tr>
<td>2 Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Analyses of variance with repeated measures, overall between effects. MMSE at baseline and course of BPSD.</td>
<td>Age, sex, SES, MMSE and GDS at baseline. Also symptoms at baseline and duration of illness.</td>
<td>Three subsyndrome factors and NPI total score.</td>
<td>Dep: NR (both MMSE and GDS)</td>
</tr>
<tr>
<td>59 Zahodne</td>
<td>2013</td>
<td>DC</td>
<td>5.5yrs</td>
<td>mean 10.1</td>
<td>6</td>
<td>Latent growth curve modelling.</td>
<td>Cognitive decline and function.</td>
<td>CUSPAD dep, continuous.</td>
<td>Dep: higher level of dep was associated with worse initial functioning and faster subsequent cognitive and functional decline.</td>
</tr>
<tr>
<td>Moderately severe dementia (MMSE 10-14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43 McCarty</td>
<td>2000</td>
<td>DC</td>
<td>24</td>
<td>3</td>
<td>1</td>
<td>Mean response of the items that loaded on each factor. Test-retest correlations and mixed model analyses.</td>
<td>By 4 severity levels based on initial MMSE score.</td>
<td>BEHAVE-AD, total score 18 (6 questions with maximum score 3).</td>
<td>The patterns are similar for all factors (including Emotional/impulsive behaviours and apathy). Those with initial MMSE scores ranging from 11 to 30 (severity levels 1 and 2) tended to show increased memory and behavioural problems across time, whereas those with initial MMSE scores ranging from 1 to 10 (severity 3) tended to show stable scores across time.</td>
</tr>
<tr>
<td>Study ID</td>
<td>Author Year</td>
<td>Design</td>
<td>Duration</td>
<td>Follow-up</td>
<td>Methodology</td>
<td>Variables</td>
<td>Findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>--------</td>
<td>----------</td>
<td>-----------</td>
<td>-------------</td>
<td>-----------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Kohler 2010</td>
<td>POP</td>
<td>6</td>
<td>3</td>
<td>Linear mixed-model analysis was used to measure the association between depressive symptom severity and cognitive decline from baseline to 3- and 6-year follow-up.</td>
<td>Age, sex, education and baseline cognition scores.</td>
<td>Stability of depression was defined as a score within the upper quartile group on 2 consecutive assessments (baseline or follow-up (F1 or F2)). This produced four groups: highly depressed at baseline only, highly depressed at follow-up only and persistently highly depressed. Participants who were persistently highly depressed over time showed a widespread pattern of decline, including memory (p&lt;0.001), processing speed (p=0.002), and global cognition (p=0.0) when compared to participants who were never highly depressed. They also performed lower on baseline measures of processing speed (p=0.04) and attention and executive function (p&lt;0.001).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Becker 2009</td>
<td>POP</td>
<td>9yrs</td>
<td>9</td>
<td>Association between dep and cognitive function scores 1992-1999 which was then examined as a predictor of the development of dementia between 2002-2007. Cox proportional hazard models.</td>
<td>Age, ventricular grade. CESD score or correlation variable of CESD and 3MSE scores.</td>
<td>No significant associations between non-dep/transiently dep/persistently dep in 1994-1998 and dementia after 1998-1999</td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Vinkers 2004</td>
<td>POP</td>
<td>4yrs</td>
<td>5</td>
<td>Separate linear mixed models. Additional annual increase of dep score per SD of cognitive function test score at baseline in those without dep at baseline (GDS15=&lt;2) (p).</td>
<td>Sex and educational level. Total GDS-15 score.</td>
<td>Dep: Global cognitive function: -0.06 (0.17); Attention: 0.08 (0.05); Processing speed: -0.03 (0.42); Immediate recall: -0.17 (0.01); Delayed recall: -0.10 (0.02).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Amieva 2008</td>
<td>POP</td>
<td>4yrs</td>
<td>7</td>
<td>Longitudinal analyses were done using a semiparametric extension of the mixed-effects linear model. The mean changes of the scores are assumed to be smooth curves, approximated by cubic splines.</td>
<td>Total CES-D score.</td>
<td>Dep: CES-D score over time before diagnosis of dementia / control: Slight increase in score with some minor fluctuation. The score increased slightly but regularly in the pre-dementia group until the diagnosis and between 8 and 7 years before diagnosis the curve of the predementia group became distinguishable from that of the control subjects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Wilson 2010</td>
<td>POP</td>
<td>8-9yrs</td>
<td>mean: 3.6</td>
<td>Change in depression scores using GEE models. The models included a term for time in years since baseline, indicators for MCI and AD, interactions of indicators with time. Also reported for depressive domains.</td>
<td>Age, sex, race, education. CES-D score ranging from 0-10. Rate of 0.04 units per year equals 1 symptom per 25 years. Also Hamilton Depression Rating Scale, ranging from 0-235.</td>
<td>Dep: CES-D - Prediagnosis of AD: 0.04 (0.004); postdiagnosis of AD: -0.00 (0.913) Hamilton - scores did not change in any of the groups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Author</td>
<td>Year</td>
<td>Group</td>
<td>Duration</td>
<td>Outcome</td>
<td>Methodology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>-----------</td>
<td>------</td>
<td>--------</td>
<td>----------</td>
<td>---------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Wilson</td>
<td>2008</td>
<td>OTHER</td>
<td>13yrs</td>
<td>mean:7.8</td>
<td>Generalised estimating equation models to analyse change in depressive symptoms before the diagnosis of AD (compared to those who never developed dementia) during the study period, with a logit-link function and a binomial error. Because preliminary analyses with quadratic terms for time showed no evidence of nonlinear change, all analyses are of linear change.</td>
<td>Age, sex, education and interactions.</td>
<td>Treating the number of reported symptoms as a proportion of the 10 possible symptoms.</td>
<td>Dep: The rate of change in depressive symptoms in the incident AD subgroup did not differ from the rate in unaffected persons before the AD diagnosis (p=0.64) or after it (p=0.62). There was no systematic change in depressive symptoms in the unaffected subgroup or in the affected subgroup before (p=0.92) or after (p=0.16) the initial MCI diagnosis.</td>
</tr>
<tr>
<td>32</td>
<td>Houde</td>
<td>2008</td>
<td>DC</td>
<td>max:10</td>
<td>max:11</td>
<td>Cox proportional hazard of the association of symptoms and covariates with progression to dementia.</td>
<td>Age, education, MMSE score, Apoe E4 status.</td>
<td>GDS score.</td>
<td>Dep: Persistent dep associated with progression to AD. MCI individuals who remained MCI: depression tended to improve in the first two years of follow-up. MCI who progressed to dementia: persistence of depression until the year prior to diagnosis as AD. After diagnosis, depression improved.</td>
</tr>
<tr>
<td>21</td>
<td>Dotson</td>
<td>2008</td>
<td>VOL</td>
<td>max 26yrs</td>
<td>NR</td>
<td>Linear mixed models using the PROC MIXED procedure in SAS. Yields information on the unique effects of each predictor, including both fixed and random effects.</td>
<td>Baseline age, time interval and interval and interactions. Sex, self-reported race, educations and scores on the primary mental abilities vocabulary test.</td>
<td>Continuous CES-D score.</td>
<td>Dep: Higher average depressive symptoms were associated with poorer performance on TMT-A and TMT-B. Individuals with higher average CES-D scores showed greater longitudinal decline on CVLT-A, long delay free recall, BIMCS and MMSE. Some interaction effects. See table 5 and figure 3.</td>
</tr>
<tr>
<td>41</td>
<td>Mackin</td>
<td>2011</td>
<td>VOL</td>
<td>3yrs</td>
<td>4</td>
<td>Participants were classified ‘MCI converters’ if they were diagnosed with dementia within 3 years of their baseline evaluation or ‘MCI cognitively stable’ if they did not progress to dementia during this interval.</td>
<td>Age, education, baseline general cognitive ability and self-reported health.</td>
<td></td>
<td>Dep: no difference in stability between cognitively stable and those who progressed to dementia.</td>
</tr>
<tr>
<td>9</td>
<td>Bielak</td>
<td>2011</td>
<td>POP</td>
<td>15yrs</td>
<td>5</td>
<td>Bivariate dual change score models.</td>
<td></td>
<td></td>
<td>Dep: the data best fit the hypothesis that depressive symptoms predict subsequent change in perceptual speed. More depressive symptoms predicted subsequently stronger declines in perceptual speed over time lags of 1 year.</td>
</tr>
</tbody>
</table>
### Comparing cognitive groups

| Author        | Year   | Setting | Months follow-up | n BPSD measures | Time between measures (months) | Details                                                                 | Covariates                               | Score                                      | Delusion / Hallucination / Misidentification |
|---------------|--------|---------|------------------|-----------------|------------------------------|------------------------------------------------------------------------|------------------------------------------|--------------------------------------------|
| Janzing       | 2000   | CH      | 12               | 3               | 6                            | Logistic regression of dep and dementia.                               | Age, sex, physical illness and somatic complaints. | Subjects with and without dementia had comparable baseline prevalences of depressive caseness (12.2% compared to 11.1, ns) and depression subcaseness (20.4% compared to 28.9%, ns). This remained stable during 12 month follow-up. |
| Blansi        | 2005   | DC      | 3-4yrs           | 3-4             | 12                           | Linear and quadratic curves were fitted to repeated symptom and MMSE measurements for each patient. Linear (increasing) or quadratic (inverse U-shaped) course as a function of MMSE scores. | Age, years of education and gender. | Age, years of education and gender. | Dep: Sign test for the analysis of a linear course (increasing) was significant p<0.01; Quadratic (inverse U shaped) not significant. |
| Bunce         | 2012   | PB      | max 12yrs        | max 4           | 4 yrs                        | Latent growth models estimating the intercept and slope of dep and anx symptoms. | Cognitive measures. | Cognitive measures. | Dep: Higher initial scores of dep significantly associated with poorer initial performance on SLMT, verbal fluency and episodic memory, dep slope NS Anx: Higher initial scores of anx associated with poorer verbal fluency, anx slope NS. |

**Psychotic symptoms**

| Author        | Year   | Setting | Months follow-up | n BPSD measures | Time between measures (months) | Details                                                                 | Covariates                               | Score                                      | Delusion / Hallucination / Misidentification |
|---------------|--------|---------|------------------|-----------------|------------------------------|------------------------------------------------------------------------|------------------------------------------|--------------------------------------------|
| Moderate dementia (MMSE 15-20) |
| Holtzer       | 2003   | DC      | 5yrs             | 11               | 6                            | GEE analyses to calculate the odds of having each of the psychopathological behaviours as a function of cognitive status in the entire sample with all available patient visits. | Controlled for age, education and sex. | Del: nMMSE 39-57: ref; 33-38:1.4 (0.0314); 26-32: 2.3 (<0.0001); 14-25: 2.4 (<0.0001); 0-13: 1.1 (0.8356) Hal: nMMSE 39-57: ref; 33-38:2.0 (0.0287); 26-32: 2.6 (0.0009); 14-25: 3.3 (0.0001); 0-13: 2.6 (0.0059). |
| Aalten        | 2005   | DC      | 24               | 5                | 6                            | Analyses of variance with repeated measures, overall between effects. MMSE at baseline and course of BPSD. | Age, sex, social class, MMSE and GDS at baseline. Also symptoms at baseline and duration of illness. | Three subsyndrome factors and NPI total score. | MMSE at baseline related to higher level of psychosis at follow-up, F=3.5, p=0.034 - GDS NR. |
Cognitive decline during entire follow-up for those who developed symptoms compared to those that did not. Patients who developed psychosis exhibited a more rapid rate of cognitive decline on average during the entire follow-up period than those who did not develop psychosis (p<0.03).

Moderately severe dementia (MMSE 10-14)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Covariates</th>
<th>Score</th>
<th>Irritability / Agitation / Wandering</th>
</tr>
</thead>
<tbody>
<tr>
<td>McShane</td>
<td>1995</td>
<td>CLIN</td>
<td>4yrs</td>
<td>NR</td>
<td>4</td>
<td>Analysis of covariance.</td>
<td>Cortical Lewy bodies, visual problems, interaction term.</td>
<td>Proportion of all interviews at which hallucinations had been rated positively.</td>
<td>Hal: Cortical Lewy bodies associated with persistent hallucinations. Those who had ever had hallucinations (even if at only one interview) had significantly lower MMSE scores at their last interview (8.5 vs. 3.5, p=0.005); Cognitive decline did not have a significant independent effect on proportion of interviews with hallucinations, sum of squares 0.010, F=0.19, p=0.67.</td>
</tr>
</tbody>
</table>

Hyperactivity symptoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Covariates</th>
<th>Score</th>
<th>Irritability / Agitation / Wandering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scarmeas</td>
<td>2007</td>
<td>NR</td>
<td>14yrs</td>
<td>max:25</td>
<td>6</td>
<td>Cox models predicting cognitive function by disruptive behavioural symptoms as time-dependent covariates. Also sundowning, also unadjusted results reported.</td>
<td>Controlled for cohort, recruitment centre, age, sex, education, baseline MMSE, baseline blessed dementia rating scale score, comorbidity index, use of cholinesterase inhibitors and use of neuroleptics.</td>
<td>Disruptive behavioural symptoms.</td>
<td>Agi: HR=1.64 (1.16-2.33) Wan: NS Irr: NS Total score: Sum (0-5): HR=1.21 (1.07-1.36); Any (0-1) HR=1.45 (1.03-2.03).</td>
</tr>
<tr>
<td>Holtzer</td>
<td>2003</td>
<td>DC</td>
<td>5yrs</td>
<td>11</td>
<td>6</td>
<td>GEE analyses to calculate the odds of having each of the psychopathological behaviours as a function of cognitive status in the entire sample with all available patient visits.</td>
<td>Controlled for age, education and sex.</td>
<td></td>
<td>Wan: mMMS 39-57: ref; 33-38:1.5 (0.0568); 26-32: 2.0 (0.0064); 14-25: 3.3 (&lt;0.0001); 0-13: 4.2 (&lt;0.0001) Irr: mMMS 39-57: ref; 33-38:3.5 (0.0016); 26-32: 3.1 (0.0001); 14-25: 3.6 (&lt;0.0001); 0-13: 9.0 (&lt;0.0001).</td>
</tr>
<tr>
<td>Aalten</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td>6</td>
<td>Analyses of variance with</td>
<td>Age, sex, SES, MMSE Three subsyndrome factors</td>
<td>Hyperactivity - Significant interaction between time and</td>
<td></td>
</tr>
</tbody>
</table>
### Repeated measures, overall between effects. MMSE at baseline and course of BPSD.

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design</th>
<th>Duration</th>
<th>Baseline Measure</th>
<th>Early Symptom</th>
<th>Duration of Illness</th>
<th>MMSE Score at Baseline</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hope</td>
<td>2001</td>
<td>CLIN</td>
<td>9 yrs</td>
<td>mean: 10.5</td>
<td>MMSE score at onset of behaviour and at death in participants included in the study for more than one year.</td>
<td>Period with dementia.</td>
<td>Lower MMSE score and death associated with wan (p=0.05). Median MMSE scores at onset suggests progression from excessive but appropriate walking, attempts to leave the home and pottering, through to clear hyperactivity that becomes increasingly aimless and inappropriate.</td>
<td></td>
</tr>
<tr>
<td>McShane</td>
<td>1998</td>
<td>CLIN</td>
<td>4 yrs</td>
<td>NR</td>
<td>Relationship between symptoms and cognitive function in first year using Pearson X² or student's t statistics as appropriate.</td>
<td></td>
<td>MMSE in year after entry lower in those with physical aggression than in those without (8.1 compared to 15.7, p=0.003) and in those with hyperactivity than in those without (9.2 compared to 16.0, p=0.003).</td>
<td></td>
</tr>
<tr>
<td>Asada</td>
<td>1999</td>
<td>DC + VOL</td>
<td>5 yrs</td>
<td>6</td>
<td>Symptom change by baseline CDR stage: Repeated measurement analysis with the PROC MIXED program based only on the data for the subjects who completed all six assessments. Four candidate models were proposed: constant correlation, correlation declining exponentially with time, no mathematical pattern and no relation. Association symptom change and level of global impairment.</td>
<td>Behavioural factor score.</td>
<td>See figure 1 and 2 Hyperactivity: CDR 2 and 3: slopes of the lines for hyperactivity showed a significant downward trend. Factor score reached its peak during the CDR 2 stage and followed a linear downward trend thereafter. Agitation: CDR 2 Significant downward trend, CDR 3 NS.</td>
<td></td>
</tr>
</tbody>
</table>

### Severe dementia (MMSE 0-9)

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design</th>
<th>Duration</th>
<th>Baseline Measure</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burgio</td>
<td>2007</td>
<td>CH</td>
<td>18</td>
<td>4</td>
<td>IRR: Staff: no difference; Obs: profoundly impaired (MMSE=&lt;7) changed little, moderately impaired (MMSE&gt;7)</td>
</tr>
<tr>
<td>Blansi</td>
<td>2005</td>
<td>DC</td>
<td>3-4 yrs</td>
<td>3-4</td>
<td>Linear and quadratic curves were fitted to repeated symptom and MMSE measurements for each patient. Linear (increasing) or quadratic (inverse U-shaped) course as a function of MMSE scores.</td>
</tr>
</tbody>
</table>
### Dementia severity not reported

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Setting</th>
<th>Months follow-up</th>
<th>n</th>
<th>BPSD measures</th>
<th>Time between measures (months)</th>
<th>Details</th>
<th>Covariates</th>
<th>Score</th>
<th>Total score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Moderate dementia (MMSE 15-20)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2005</td>
<td>DC</td>
<td>24</td>
<td>5</td>
<td></td>
<td>6</td>
<td>Analyses of variance with repeated measures. MMSE at baseline and course of BPSD</td>
<td>Age, sex, SES, MMSE and GDS at baseline. Also symptoms at baseline and duration of illness</td>
<td>Three subsyndrome factors and NPI total score</td>
<td>Significant interaction between time and GDS score and the NPI total score, $F=4.9, p=0.008$. Severe dementia: scores decreased, mild dementia: scores increased - MMSE NR</td>
</tr>
<tr>
<td><strong>Dementia severity not reported</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>1997</td>
<td>NR</td>
<td>mean 37.1</td>
<td>6</td>
<td></td>
<td>6</td>
<td>Matched sample t-tests</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Elation

No results

### Sleep problems

No results

### Total BPSD score

- **Agi:** Physical non-aggressive behaviour: those with moderate or severe impairment increased twice as much as those who were cognitively intact at baseline, average increases were 0.30, 0.35 and 0.14. Verbally non-aggressive behaviour: all groups showed relatively constant levels over time, with the group with moderate levels of impairment manifesting consistently higher levels of agitation. Irr: Both types of aggressive behaviours show increases over time, not significantly influenced by cognitive function.

- **Agi:** NS for any year Pacing: Significant yearly change from baseline to year 1 (0.39 points, $p=0.003$) Irr: NS for any year
Reference numbers refer to the Online Reference List

Papers from the same study groups:
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece)
2 Maasbed study
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol)
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich)
5 Hope et al. (Oxford)

Settings
DC=Dementia or memory clinic
POP=Population-based
CH=Care home
CLIN=Referred by clinicians
VOL=Volunteers
NR=Not reported

BPSD= behavioural and psychological symptoms of dementia
Apa=apathy
Dep=depression
Anx=anxiety
Irr=irritability/aggression
Agi=agitation
Hal=hallucination
Per=persecution
Mis=misidentification
Sle=sleep problems
Wan=wandering
Ela=elatio
Table DS6 Adherence to the PRISMA reporting guidelines

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review, meta-analysis, or both.</td>
<td>Title page</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structured summary</td>
<td>2</td>
<td>Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.</td>
<td>According to journal guidelines</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
<td>Introduction section</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).</td>
<td>Not relevant.</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and registration</td>
<td>5</td>
<td>Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.</td>
<td>Not available</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.</td>
<td>Methods – eligibility criteria</td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.</td>
<td>Methods – search methods</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.</td>
<td>eFigure1</td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).</td>
<td>Methods – data synthesis</td>
</tr>
<tr>
<td>----------------</td>
<td>---</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Data collection process</td>
<td>10</td>
<td>Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.</td>
<td>Methods – data synthesis</td>
</tr>
<tr>
<td>Data items</td>
<td>11</td>
<td>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</td>
<td>Methods – data synthesis</td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>12</td>
<td>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Summary measures</td>
<td>13</td>
<td>State the principal summary measures (e.g., risk ratio, difference in means).</td>
<td>Methods – data synthesis</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>15</td>
<td>Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>16</td>
<td>Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**RESULTS**

<p>| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | Results – characteristics – search results (text box) |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | eTable 1 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | Not assessed |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | No interventions. Results Figure 2 and Figure 3 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | Not applicable |</p>
<table>
<thead>
<tr>
<th>Risk of bias across studies</th>
<th>Present results of any assessment of risk of bias across studies (see Item 15).</th>
<th>Not assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional analysis</td>
<td>Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**DISCUSSION**

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).</th>
<th>Discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limitations</td>
<td>Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).</td>
<td>Discussion</td>
</tr>
<tr>
<td>Conclusions</td>
<td>Provide a general interpretation of the results in the context of other evidence, and implications for future research.</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

**FUNDING**

| Funding                    | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Acknowlegements |

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org)
Online reference list of included studies


Longitudinal course of behavioural and psychological symptoms of dementia: systematic review
Rianne M. van der Linde, Tom Dening, Blossom C. M. Stephan, A. Matthew Prina, Elizabeth Evans and Carol Brayne
BJP published online August 4, 2016 Access the most recent version at DOI: 10.1192/bjp.bp.114.148403

Supplementary Material
Supplementary material can be found at: http://bjp.rcpsych.org/content/suppl/2016/07/25/bjp.bp.114.148403.DC1.html

References
This article cites 0 articles, 0 of which you can access for free at: http://bjp.rcpsych.org/content/early/2016/07/21/bjp.bp.114.148403#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

P<P
Published online 2016-08-04T00:05:10-07:00 in advance of the print journal.

You can respond to this article at http://bjp.rcpsych.org/letters/submit/bjprcpsych;bjp.bp.114.148403v1

Downloaded from http://bjp.rcpsych.org/ on September 12, 2016
Published by The Royal College of Psychiatrists

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To subscribe to The British Journal of Psychiatry go to: http://bjp.rcpsych.org/site/subscriptions/